var title_f12_11_12464="Pentameric IgM structure";
var content_f12_11_12464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pentameric IgM structure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 462px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    IgM exists as a monomer when located on the surface of B cells and as multimers in association with an additional polypeptide chain, the J chain, when secreted. The monomers are crosslinked by disulfide bonds to each other and to the J chain. IgM can also form hexamers that lack a J chain. 1 = light chain (variable region); 2 = light chain (constant region); 3 = heavy chain (variable region); 4, 5, 6, and 7 = heavy chain (constant regions 1, 2, 3 and 4 [CH1 - CH4]).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12464=[""].join("\n");
var outline_f12_11_12464=null;
var title_f12_11_12465="Blepharitis";
var content_f12_11_12465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blepharitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lids demonstrate findings of blepharitis: diffuse eyelid margin thickening and hyperemia with lash crusts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trobe, JD. The Eyes Have It: An interactive teaching and assessment program on vision care. WK Kellogg Eye Center, University of Michigan. Copyright &copy; Jonathan D Trobe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12465=[""].join("\n");
var outline_f12_11_12465=null;
var title_f12_11_12466="Dissection of the paraesophageal hernia sac and right crus";
var content_f12_11_12466=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dissection of the paraesophageal hernia sac and right crus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows the dissection of the paraesophageal hernia sac from the right crus. The procedure is performed by the laparoscopic technique. The arrows indicate the edge of the right crus. The forceps are retracting the hernia sac.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Rosen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12466=[""].join("\n");
var outline_f12_11_12466=null;
var title_f12_11_12467="Subacute cutaneous lupus - annular plaques";
var content_f12_11_12467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subacute cutaneous lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, annular plaques with scale are present on this patient with subacute cutaneous lupus erythematosus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission: from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12467=[""].join("\n");
var outline_f12_11_12467=null;
var title_f12_11_12468="CXR of Eisenmenger syndrome";
var content_f12_11_12468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest x-ray in a patient with Eisenmenger syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This chest x-ray of a patient with Eisenmenger syndrome secondary to an atrial septal defect demonstrates cardiomegaly due to right heart enlargement, prominence of the central pulmonary arteries, and peripheral \"pruning\" of the pulmonary vasculature (abrupt attenuation and/or termination of peripheral pulmonary artery branches).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Heidi Connolly, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12468=[""].join("\n");
var outline_f12_11_12468=null;
var title_f12_11_12469="Clinical features and diagnosis of sporotrichosis";
var content_f12_11_12469=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of sporotrichosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12469/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12469/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12469/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12469/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12469/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12469/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/11/12469/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporotrichosis is a subacute to chronic infection caused by the dimorphic fungus Sporothrix schenckii. Infection usually involves cutaneous and subcutaneous tissues but can occasionally occur in other sites, primarily in immunocompromised patients. Activities associated with the development of sporotrichosis include landscaping, rose gardening, and other activities that involve inoculation of soil through the skin.",
"   </p>",
"   <p>",
"    The typical and atypical clinical manifestations of sporotrichosis and the diagnosis and treatment of these infections will be reviewed here. Mycology and epidemiology of sporotrichosis are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8134?source=see_link\">",
"     \"Basic biology and epidemiology of sporotrichosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34822?source=see_link\">",
"     \"Treatment of sporotrichosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporotrichosis usually arises after soil, moss, or other organic material containing the fungus is inoculated into the skin or subcutaneous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with pulmonary infection develop infection after inhalation of S. schenckii conidia; some cases of disseminated infection presumably also follow inhalation.",
"   </p>",
"   <p>",
"    The typical host with lymphocutaneous sporotrichosis is a healthy individual with an outdoor occupation or avocation that provides exposure to the fungus. Infections involving osteoarticular structures, lungs, meninges, and other viscera are uncommon and occur most often in individuals with underlying illnesses including [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcoholism",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Chronic obstructive pulmonary disease",
"     </li>",
"     <li>",
"      AIDS",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Lymphocutaneous sporotrichosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocutaneous sporotrichosis is the most common form of sporotrichosis seen in clinical practice. Days to weeks after cutaneous inoculation of the fungus, a papule develops at the site of inoculation. This primary lesion usually ulcerates but may remain nodular with overlying erythema; drainage from the lesion is not grossly purulent and has no odor. Similar lesions subsequently occur along lymphatic channels proximal to the original lesion, a finding called sporotrichoid spread or nodular lymphangitis (",
"    <a class=\"graphic graphic_picture graphicRef65985 graphicRef50115 \" href=\"UTD.htm?24/4/24647\">",
"     picture 1A-B",
"    </a>",
"    ). Pain is generally mild and systemic symptoms are typically absent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis for this form of sporotrichosis includes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nontuberculous mycobacterial infection, especially M. marinum",
"     </li>",
"     <li>",
"      Nocardia infections, particularly N. brasiliensis",
"     </li>",
"     <li>",
"      Leishmania brasiliensis infection",
"     </li>",
"     <li>",
"      Tularemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, many other fungal, bacterial, and viral infections rarely cause a lymphocutaneous syndrome (also called nodular lymphangitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11942?source=see_link&amp;anchor=H5#H5\">",
"     \"Lymphangitis\", section on 'Nodular lymphangitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients have a chronic, fixed cutaneous lesion; this form is seen most often in endemic regions in South America (",
"    <a class=\"graphic graphic_picture graphicRef74340 \" href=\"UTD.htm?27/31/28158\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74515 \" href=\"UTD.htm?6/59/7094\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef56900 \" href=\"UTD.htm?13/15/13556\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/10\">",
"     10",
"    </a>",
"    ]. These fixed lesions, frequently found on the face and extremities, tend to be plaque-like or verrucous, but they also may ulcerate. The cutaneous form will not resolve without therapy although the lesion may appear to regress and flare periodically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pulmonary sporotrichosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for pulmonary sporotrichosis include chronic obstructive pulmonary disease and alcohol use [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. Symptoms mimic those of tuberculosis, including constitutional complaints of fever, night sweats, weight loss, and fatigue as well as respiratory complaints including dyspnea, cough, purulent sputum, and hemoptysis. The chest radiographic findings are also similar to tuberculosis: unilateral or bilateral upper lobe cavities with variable amounts of fibrosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    scattered nodular lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51548 \" href=\"UTD.htm?23/52/24399\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some patients with pulmonary involvement have evidence of dissemination to skin, osteoarticular structures, or viscera. Almost without exception, untreated pulmonary sporotrichosis progresses to death. The differential diagnosis includes tuberculosis; chronic fungal infections, especially histoplasmosis; and sarcoidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Osteoarticular sporotrichosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like pulmonary sporotrichosis, this uncommon manifestation of sporotrichosis is found most often in middle-aged men and appears to occur more frequently in alcoholics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Disease usually arises from hematogenous spread, but may also occur after local inoculation. Infection may involve one or several joints, and may or may not be accompanied by overlying cutaneous lesions. The most commonly affected joints are the knee, elbow, wrist, and ankle.",
"   </p>",
"   <p>",
"    Joint infection is more common than osteomyelitis. When bone is involved, it usually occurs contiguous to an infected joint rather than as isolated osteomyelitis. Bursitis and tenosynovitis have been reported, sometimes presenting as a nerve entrapment syndrome.",
"   </p>",
"   <p>",
"    Osteoarticular sporotrichosis is chronic with progressive decreased range of motion, pain, and swelling. Draining sinuses can be a late manifestation. Because diagnosis is often delayed, the outcome is poor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Meningeal sporotrichosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningitis is a rare manifestation of sporotrichosis, occurring mostly in those with cellular immune defects, such as lymphoma or AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Meningitis may be an isolated finding or a manifestation of disseminated disease. In those patients who have isolated meningitis, the course is usually chronic and symptoms include several weeks of fever and headache. The CSF findings are similar to those seen with tuberculosis or cryptococcosis, including lymphocytic pleocytosis, elevated protein, and decreased glucose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\", section on 'Cerebrospinal fluid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Disseminated sporotrichosis and other localized visceral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated sporotrichosis is very uncommon, with cases occurring primarily in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/6,12-14\">",
"     6,12-14",
"    </a>",
"    ]. S. schenckii rarely causes infection of the pericardium, eye, perirectal tissues, larynx, breast, epididymis, spleen, liver, bone marrow, and lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/1,15,16\">",
"     1,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105584859\">",
"    <span class=\"h2\">",
"     Sporotrichosis in patients with HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most case reports of sporotrichosis in HIV-infected patients have noted the propensity for severe infection and occurrence mostly in patients with advanced AIDS with very low CD4 counts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/12,14,15\">",
"     12,14,15",
"    </a>",
"    ]. The largest series of cases of sporotrichosis among HIV-infected patients has been reported from Rio de Janeiro, Brazil where an ongoing zoonotic outbreak has been traced back to domestic cats [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/13\">",
"     13",
"    </a>",
"    ]. Among the 21 cases described, disseminated sporotrichosis and lymphocutaneous sporotrichosis were noted in seven patients each. Five others had widespread cutaneous lesions, and two had fixed cutaneous lesions with no spread. Only two of the patients who had disseminated infection had meningitis. The mean CD4 count was",
"    <span class=\"nowrap\">",
"     364/microliter",
"    </span>",
"    (range 22 to 1100). Thus, there is likely a wider spectrum of infections in patients who have HIV infection than had been previously thought. This observation could be due to earlier diagnosis during an identified outbreak, or it is possible that a less virulent strain caused this outbreak. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis is not difficult when a patient presents with classic lymphocutaneous sporotrichosis, since the clinical features are highly suggestive. However, diagnosis of the less classic forms of sporotrichosis, such as osteoarticular or visceral disease, is almost always delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture is the gold standard for establishing a diagnosis of sporotrichosis and is also the most sensitive method. Aspirated material from a lesion, sample from a tissue biopsy, sputum, or body fluids should be inoculated onto Sabouraud&rsquo;s dextrose agar and incubated at room temperature. Incubation at this temperature facilitates growth of the mycelial phase of S. schenckii with the characteristic arrangement of conidia on the hyphae.",
"   </p>",
"   <p>",
"    Growth usually appears within five days, but rarely can take several weeks. To ensure that the fungus is S. schenckii, the mold phase should be converted to the yeast phase on blood agar at 37&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/1\">",
"     1",
"    </a>",
"    ]. Rarely, S. schenckii has been grown from culture of blood using the lysis-centrifugation method [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual histopathologic picture is that of a mixed granulomatous and pyogenic process. The organisms may not be visualized even with special stains for fungi, such as Gomori methenamine silver and periodic acid Schiff (PAS) stains, because the number of organisms is often small. When found, this fungus is 3 to 5 micron in diameter, oval to cigar-shaped, and may show multiple buds.",
"   </p>",
"   <p>",
"    Rarely, asteroid bodies consisting of a central basophilic yeast surrounded by eosinophilic material radiating outward like spokes on a wheel, can be seen (",
"    <a class=\"graphic graphic_picture graphicRef73691 \" href=\"UTD.htm?28/38/29284\">",
"     picture 5",
"    </a>",
"    ). This reaction is thought to represent either antigen-antibody complexes or disintegrating neutrophils and is not specific for sporotrichosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, serology is not useful in the diagnosis of sporotrichosis. A group in Brazil has developed an enzyme immunoassay for serologic testing for S. schenckii with a reported sensitivity of 90 percent and a specificity of 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12469/abstract/18\">",
"     18",
"    </a>",
"    ], but the role of this assay remains to be evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sporotrichosis is a subacute to chronic infection caused by the dimorphic fungus Sporothrix schenckii. Infection usually involves cutaneous and subcutaneous tissues but can occasionally occur in other sites. Activities associated with the development of sporotrichosis include landscaping, rose gardening, and other activities that involve inoculation of soil through the skin. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical host with lymphocutaneous sporotrichosis is a healthy individual with an outdoor occupation or avocation that provides exposure to the fungus. Infections involving osteoarticular structures, lungs, meninges, and other viscera are uncommon and occur most often in individuals with underlying illnesses including alcoholism, diabetes mellitus, chronic obstructive pulmonary disease, and AIDS. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Days to weeks after cutaneous inoculation of the fungus, a papule develops at the site of inoculation. This primary lesion usually ulcerates but may remain nodular with overlying erythema. Similar lesions subsequently occur along lymphatic channels proximal to the original lesion (",
"      <a class=\"graphic graphic_picture graphicRef65985 graphicRef50115 \" href=\"UTD.htm?24/4/24647\">",
"       picture 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Lymphocutaneous sporotrichosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of pulmonary sporotrichosis mimic those of tuberculosis including constitutional complaints of fever, night sweats, weight loss, and fatigue as well as respiratory complaints including dyspnea, cough, purulent sputum, and hemoptysis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pulmonary sporotrichosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteoarticular sporotrichosis usually arises from hematogenous spread, but may also occur after local inoculation. Infection may involve one or several joints, and may or may not be accompanied by overlying cutaneous lesions. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Osteoarticular sporotrichosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Culture is the gold standard for establishing a diagnosis of sporotrichosis and is also the most sensitive method. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Culture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The usual histopathologic picture is that of a mixed granulomatous and pyogenic process. The organisms may not be visualized even with special stains for fungi, such as Gomori",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/57/3989?source=see_link\">",
"       methenamine",
"      </a>",
"      silver and periodic acid Schiff (PAS) stains, because the number of organisms is often small. When found, this fungus is 3 to 5 micron in diameter, oval to cigar-shaped, and may show multiple buds. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kwon-Chung KJ, Bennett JE. Sporotrichosis. In: Medical Mycology, Lea &amp; Febiger, Philadelphia 1992. p.707.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/2\">",
"      Kauffman CA. Sporotrichosis. Clin Infect Dis 1999; 29:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/3\">",
"      Pluss JL, Opal SM. Pulmonary sporotrichosis: review of treatment and outcome. Medicine (Baltimore) 1986; 65:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/4\">",
"      Kauffman CA, Pappas PG, McKinsey DS, et al. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis 1996; 22:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/5\">",
"      Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group. Am J Med 1993; 95:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/6\">",
"      Bustamante, B, Lama, J, Mosquera, C, et al. Sporotrichosis in human immunodeficiency virus infected Peruvian patients. Two case reports and literature review. Infect Dis Clin Pract 2009; 17:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/7\">",
"      Pappas PG, Tellez I, Deep AE, et al. Sporotrichosis in Peru: description of an area of hyperendemicity. Clin Infect Dis 2000; 30:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/8\">",
"      Kostman JR, DiNubile MJ. Nodular lymphangitis: a distinctive but often unrecognized syndrome. Ann Intern Med 1993; 118:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/9\">",
"      Smego RA Jr, Castiglia M, Asperilla MO. Lymphocutaneous syndrome. A review of non-sporothrix causes. Medicine (Baltimore) 1999; 78:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/10\">",
"      da Rosa AC, Scroferneker ML, Vettorato R, et al. Epidemiology of sporotrichosis: a study of 304 cases in Brazil. J Am Acad Dermatol 2005; 52:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/11\">",
"      Tiwari A, Malani AN. Primary pulmonary sporotrichosis: Case report and review of the literature. Infect Dis Clin Pract 2012; 20:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/12\">",
"      Donabedian H, O'Donnell E, Olszewski C, et al. Disseminated cutaneous and meningeal sporotrichosis in an AIDS patient. Diagn Microbiol Infect Dis 1994; 18:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/13\">",
"      Freitas DF, de Siqueira Hoagland B, do Valle AC, et al. Sporotrichosis in HIV-infected patients: report of 21 cases of endemic sporotrichosis in Rio de Janeiro, Brazil. Med Mycol 2012; 50:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/14\">",
"      Bolao F, Podzamczer D, Ventin M, Gudiol F. Efficacy of acute phase and maintenance therapy with itraconazole in an AIDS patient with sporotrichosis. Eur J Clin Microbiol Infect Dis 1994; 13:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/15\">",
"      Kurosawa A, Pollock SC, Collins MP, et al. Sporothrix schenckii endophthalmitis in a patient with human immunodeficiency virus infection. Arch Ophthalmol 1988; 106:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/16\">",
"      Wilson DE, Mann JJ, Bennett JE, Utz JP. Clinical features of extracutaneous sporotrichosis. Medicine (Baltimore) 1967; 46:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/17\">",
"      Kosinski RM, Axelrod P, Rex JH, et al. Sporothrix schenckii fungemia without disseminated sporotrichosis. J Clin Microbiol 1992; 30:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12469/abstract/18\">",
"      Bernardes-Engemann AR, Costa RC, Miguens BR, et al. Development of an enzyme-linked immunosorbent assay for the serodiagnosis of several clinical forms of sporotrichosis. Med Mycol 2005; 43:487.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2457 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12469=[""].join("\n");
var outline_f12_11_12469=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Lymphocutaneous sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pulmonary sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Osteoarticular sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Meningeal sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Disseminated sporotrichosis and other localized visceral infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105584859\">",
"      Sporotrichosis in patients with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2457\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2457|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/52/24399\" title=\"diagnostic image 1\">",
"      Radiograph pulm sporotrich",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2457|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/63/14320\" title=\"picture 1A\">",
"      Lymphocutaneous sporotrichosis leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/31/12788\" title=\"picture 1B\">",
"      Lymphocutaneous sporotrichosis arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/31/28158\" title=\"picture 2\">",
"      Cutaneous sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/59/7094\" title=\"picture 3\">",
"      Fixed cutaneous sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/15/13556\" title=\"picture 4\">",
"      Multifocal cutaneous lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/38/29284\" title=\"picture 5\">",
"      Sporo asteroid body",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8134?source=related_link\">",
"      Basic biology and epidemiology of sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=related_link\">",
"      Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11942?source=related_link\">",
"      Lymphangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34822?source=related_link\">",
"      Treatment of sporotrichosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_11_12470="The heavy chain diseases";
var content_f12_11_12470=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The heavy chain diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12470/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12470/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12470/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12470/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12470/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12470/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/11/12470/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heavy chain diseases are rare B-cell proliferative disorders characterized by the production of a monoclonal (M) protein consisting of a portion of the immunoglobulin heavy chain without a bound light chain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The heavy chain in heavy chain disease is often incomplete or truncated and a sharp, localized peak may not be seen on the electrophoretic tracing of serum or urine.",
"   </p>",
"   <p>",
"    The heavy chain diseases will be reviewed here. Heavy chain deposition disease is a different disorder that is discussed in detail elsewhere, in which abnormal heavy chains or short (truncated) heavy chains cause fibrillar or granular tissue deposits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=see_link\">",
"     \"Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three types of heavy chain disease (HCD) are recognized, based upon the class of immunoglobulin heavy chain produced (eg, alpha, gamma, mu) by the malignant cell [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alpha HCD is a form of Mucosa associated lymphoid tissue (MALT) lymphoma that is also called immunoproliferative small intestinal disease (IPSID), Mediterranean lymphoma, or Seligmann disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Alpha HCD'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\", section on 'Lymphoma of the small intestine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gamma HCD (Franklin's disease) is typically associated with the presence of a systemic lymphoma, often of mixed lymphoid-plasmacytic character. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Gamma HCD'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Mu HCD has clinical features resembling small lymphocytic",
"      <span class=\"nowrap\">",
"       lymphoma/chronic",
"      </span>",
"      lymphocytic leukemia, often with distinctive vacuolated",
"      <span class=\"nowrap\">",
"       lymphocytes/plasma",
"      </span>",
"      cells in the bone marrow. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Mu HCD'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prognosis of the HCDs is variable, and no standardized effective treatment programs are available except for alpha-HCD, which in its early stage may respond to antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Alpha HCD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     The normal immunoglobulin molecule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunoglobulin molecule is composed of two heavy and two light chains, joined by disulfide bonds (",
"    <a class=\"graphic graphic_figure graphicRef56393 \" href=\"UTD.htm?1/2/1071\">",
"     figure 1",
"    </a>",
"    ). The normal heavy chain constant region (CH region) has a number of domains, of which CH1 is responsible for light chain binding. In the absence of an associated light chain, the CH1 domain binds to heat shock protein 78 (heavy chain binding protein, BiP), and the heavy chain undergoes proteasomal degradation rather than secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, normal heavy chains without light chains are not detected in the serum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7318?source=see_link&amp;anchor=H2#H2\">",
"     \"Structure of immunoglobulins\", section on 'Structure of immunoglobulin proteins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     The abnormal heavy chain in HCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the heavy chain diseases, noncontiguous deletions in the switch-CH1 region prevent binding of the abnormal heavy chain to light chains as well as to heat shock protein 78, thereby avoiding proteasomal degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The heavy chains are then secreted into the plasma (or jejunal fluid in the case of alpha HCD) and, if small enough, may appear in the urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Making the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with one of the heavy chain diseases will come to the attention of clinicians in two different ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For consideration of the diagnosis of a localized or diffuse lymphomatous process",
"      <span class=\"nowrap\">",
"       and/or:",
"      </span>",
"     </li>",
"     <li>",
"      For evaluation of the presence of a monoclonal protein in the serum, urine, or tissues. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H4#H4\">",
"       \"Recognition of monoclonal proteins\", section on 'Clonal size'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specific diagnosis of one of the HCDs, along with the diagnosis of the underlying plasma",
"    <span class=\"nowrap\">",
"     cell/lymphocytic",
"    </span>",
"    clonal disorder, can be made via a combination of studies of tissues and analysis of serum or urine samples.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Tissue diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemical staining of an affected tissue (eg, mass lesion, enlarged lymph node(s), bone marrow involvement, hepatosplenomegaly) shows the presence of a clonal population of cells staining positively for a heavy chain but negative for both kappa and lambda light chains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Serum and urine studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of finding a monoclonal \"spike\" on serum or urine protein electrophoresis is variable, and differs among the three types of HCD. On immunofixation, the abnormal protein, if present, consists of a heavy chain (ie, alpha, gamma, mu) without an associated light chain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H13#H13\">",
"     \"Recognition of monoclonal proteins\", section on 'False negative results'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In alpha HCD, there is not a localized band or sharp peak on electrophoresis, presumably because of the tendency of these chains to form polymers of different sizes. In some patients, the abnormal proteins are found in jejunal fluid but not in the serum. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\", section on 'Lymphoma of the small intestine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In gamma HCD, the electrophoretic tracing may appear broad and heterogeneous rather than showing a localized band.",
"     </li>",
"     <li>",
"      In mu HCD, panhypogammaglobulinemia is a prominent feature and a localized band is found in only 40 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ALPHA HCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha HCD (also called immunoproliferative small intestinal disease (IPSID), Mediterranean lymphoma, Seligmann disease) is a form of MALT lymphoma, with the same histologic features of MALT type GI lymphomas with marked plasma cell differentiation. It is the most common form of HCD and occurs in patients from the Mediterranean region or Middle East, usually young males, and is often associated with relatively poor sanitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\", section on 'Lymphoma of the small intestine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to alpha HCD are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\", section on 'Lymphoma of the small intestine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, the gastrointestinal tract is involved in alpha HCD, resulting in abdominal pain, severe malabsorption with chronic diarrhea, steatorrhea, and loss of weight. Growth retardation (in children), digital clubbing, and mesenteric lymphadenopathy may also be present.",
"   </p>",
"   <p>",
"    Infiltration of the jejunal mucosa with plasmacytoid cells is the most frequent pathologic feature. The duodenum and ileum are less often affected. The diagnosis depends upon the recognition of a monoclonal alpha heavy chain without an associated light chain in the serum, urine, intestinal secretions, or cells infiltrating the intestinal mucosa.",
"   </p>",
"   <p>",
"    The serum protein electrophoretic pattern is normal in one-half of cases, and in the remainder an unimpressive broad band may appear in the alpha-2 or beta mobility regions. The amount of alpha heavy chain in the urine is small.",
"   </p>",
"   <p>",
"    In the absence of therapy, alpha HCD typically is progressive and fatal. The usual treatment is with antibiotics such as tetracyclines and eradication of any concurrent infection (eg, parasites, viruses, Helicobacter pylori, Campylobacter jejuni). Patients who do not respond adequately to antibiotics are treated with chemotherapy similar to that used to treat non-Hodgkin lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\", section on 'Campylobacter jejuni'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GAMMA HCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with gamma HCD typically present with systemic symptoms, lymphadenopathy, splenomegaly,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anemia, and occasionally with palatal and uvular swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. The median age of patients with gamma HCD is 60 to 70 years, although the condition has been noted in persons younger than age 20.",
"   </p>",
"   <p>",
"    In the largest reported series of 23 patients with gamma HCD seen at the Mayo Clinic, the following findings were present [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Monoclonal spike on electrophoresis &mdash; 83 percent",
"     </li>",
"     <li>",
"      Lymphadenopathy &mdash; 35 percent",
"     </li>",
"     <li>",
"      Hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      &mdash; 35 percent",
"     </li>",
"     <li>",
"      Bone marrow involvement &mdash; 32 percent",
"     </li>",
"     <li>",
"      Splenomegaly &mdash; 30 percent",
"     </li>",
"     <li>",
"      Skin involvement &mdash; 30 percent",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL",
"      </span>",
"      &mdash; 17 percent",
"     </li>",
"     <li>",
"      Hepatomegaly &mdash; 4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical findings ranged from an asymptomatic state (eg, monoclonal gammopathy of undetermined significance, MGUS) to an aggressive lymphoproliferative process.",
"   </p>",
"   <p>",
"    Autoimmune manifestations are seen in about one-third of patients (eg, idiopathic thrombocytopenia purpura, hemolytic anemia, vasculitis, systemic lupus erythematosus, rheumatoid arthritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/1,3,9,10\">",
"     1,3,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gamma HCD is typically associated with a polymorphous infiltrate, including admixtures of lymphocytes, plasmacytoid lymphocytes, plasma cells, immunoblasts, and eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/1,3,11,12\">",
"     1,3,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The electrophoretic pattern often shows a broad-based band more suggestive of a polyclonal increase but the gamma chains are monoclonal. The diagnosis is established by immunofixation, which shows that the abnormal protein consists only of gamma heavy chains without associated light chains. The monoclonal gamma chains have significant deletions of amino acids, including the CH1 domain of the constant region.",
"   </p>",
"   <p>",
"    Treatment is indicated",
"    <strong>",
"     only",
"    </strong>",
"    for symptomatic patients. Therapy has consisted of chemotherapy with varying combinations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (eg, the CHOP regimen (",
"    <a class=\"graphic graphic_table graphicRef66136 \" href=\"UTD.htm?0/54/876\">",
"     table 1",
"    </a>",
"    )) or, if the abnormal cells express CD20, the anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/2,3,9,13,14\">",
"     2,3,9,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Mayo Clinic series of 23 patients cited above, management was as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment was not felt to be needed in five patients, all of whom had stable disease at follow-up.",
"     </li>",
"     <li>",
"      Chemotherapy was given to 16 patients, of whom six attained a complete clinical response. The remaining 10 patients had persistence of clinical disease, leading to death due to progressive disease or disease-related complications (eg, infection, autoimmune complications).",
"     </li>",
"     <li>",
"      Two patients were considered to be too sick to receive treatment; both died within five months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis of gamma HCD is variable and ranges from the asymptomatic presence of a stable monoclonal heavy chain in the serum or urine (eg, MGUS) to a rapidly progressive downhill course of a few weeks' duration (eg, highly aggressive lymphoma). In the Mayo Clinic series, the median survival was 7.4 years with an extremely wide range (1 month to more than 21 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MU HCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mu HCD is the least common of the HCDs and is characterized by a monoclonal mu chain fragment in the serum. It has features resembling chronic lymphocytic",
"    <span class=\"nowrap\">",
"     leukemia/small",
"    </span>",
"    lymphocytic lymphoma (eg, anemia, hepatosplenomegaly), although peripheral adenopathy is less common than in CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/1\">",
"     1",
"    </a>",
"    ]. Osteolytic lesions or pathologic fractures have been reported in occasional patients. Unlike alpha and gamma HCD, some patients with mu HCD have increased free light chain secretion (Bence Jones proteinuria), and may develop cast nephropathy or amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristic vacuolated plasma cells or lymphoid cells are commonly seen in the bone marrow and panhypogammaglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/2,13,17\">",
"     2,13,17",
"    </a>",
"    ]. The serum protein electrophoretic pattern is usually normal except for hypogammaglobulinemia.",
"   </p>",
"   <p>",
"    The course of mu HCD is variable, and survival ranges from a few months to many years. Reported treatment has been similar to that of patients with chronic lymphocytic leukemia (eg, glucocorticoids, alkylating agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12470/abstract/15,18\">",
"     15,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heavy chain diseases (HCDs) are rare B-cell proliferative disorders characterized by the production of a monoclonal (M) protein consisting of a portion of the immunoglobulin heavy chain without a bound light chain. The heavy chain is often incomplete or truncated and a sharp, localized peak may not be seen on the electrophoretic tracing of serum or urine. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'The abnormal heavy chain in HCD'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of the HCDs is that of a patient with a low-grade B-cell malignancy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alpha HCD &mdash; The gastrointestinal tract is most commonly involved in alpha-HCD, resulting in abdominal pain, malabsorption with chronic diarrhea, steatorrhea, and loss of weight. Infiltration of the jejunal mucosa with plasmacytoid cells is the most frequent pathologic feature. The diagnosis depends upon the recognition of a monoclonal alpha heavy chain without an associated light chain in the serum, urine, intestinal secretions, or the cells infiltrating the intestinal mucosa. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Alpha HCD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gamma HCD &mdash; Patients with gamma HCD most often present with systemic symptoms, lymphadenopathy, hepatosplenomegaly, and anemia, and occasionally with palatal and uvular swelling. Autoimmune manifestations are seen in about one-third of patients. Gamma HCD is typically associated with a polymorphous infiltrate, including admixtures of lymphocytes, plasmacytoid lymphocytes, plasma cells, immunoblasts, and eosinophils. The abnormal protein consists only of gamma heavy chains without an associated light chain. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Gamma HCD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mu HCD &mdash; Mu chain HCD has features resembling chronic lymphocytic leukemia",
"      <span class=\"nowrap\">",
"       (CLL)/small",
"      </span>",
"      lymphocytic lymphoma (eg, anemia, hepatosplenomegaly), although peripheral adenopathy is less commonly seen than in CLL. Vacuolated",
"      <span class=\"nowrap\">",
"       lymphocytes/plasma",
"      </span>",
"      cells in the bone marrow and panhypogammaglobulinemia are commonly seen. The abnormal protein consists only of mu heavy chains without an associated light chain. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Mu HCD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of one of the HCDs can be made on histopathologic examination of affected tissues",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    analysis of serum or urine samples by electrophoresis and immunofixation. A typical monoclonal \"spike\" in the serum or urine may not always be present. On serum or urine immunofixation or immunohistochemical staining of affected tissues, the abnormal protein consists of a heavy chain (ie, alpha, gamma, mu) without an associated light chain. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Making the diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports concerning the treatment of the heavy chain diseases are largely anecdotal. Accordingly, with the exception of initial treatment of alpha HCD with appropriate antibiotics, which can be curative in some cases, all of the recommendations given below are based upon low quality evidence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alpha HCD &mdash; We recommend eradication of any concurrent infection (eg, parasites, viruses, Helicobacter pylori, Campylobacter jejuni) with appropriate antibiotics as initial treatment of alpha HCD (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For those with symptomatic disease who do not respond adequately to antibiotics, chemotherapy similar to that used to treat non-Hodgkin lymphoma, such as the CHOP regimen (",
"    <a class=\"graphic graphic_table graphicRef66136 \" href=\"UTD.htm?0/54/876\">",
"     table 1",
"    </a>",
"    ), is most appropriate.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gamma HCD &mdash; We suggest that treatment of gamma HCD is indicated only for symptomatic patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Appropriate chemotherapy would include such regimens as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or regimens used to treat B-cell lymphoma, such as the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and prednisone, with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (eg, the CHOP regimen, (",
"      <a class=\"graphic graphic_table graphicRef66136 \" href=\"UTD.htm?0/54/876\">",
"       table 1",
"      </a>",
"      )) or, if the abnormal cells express CD20, the anti-CD20 antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Gamma HCD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mu HCD &mdash; Treatment for symptomatic patients with mu HCD is similar to that employed in patients with chronic lymphocytic leukemia (eg, glucocorticoids, alkylating agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Mu HCD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link&amp;anchor=H28#H28\">",
"       \"Overview of the treatment of chronic lymphocytic leukemia\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Grogan TM, Van Camp B, Kyle RA, et al. Plasma cell neoplasms. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001. p.142.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/2\">",
"      Wahner-Roedler DL, Kyle RA. Heavy chain diseases. Best Pract Res Clin Haematol 2005; 18:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/3\">",
"      Munshi NC, Digumarthy S, Rahemtullah A. Case records of the Massachusetts General Hospital. Case 13-2008. A 46-year-old man with rheumatoid arthritis and lymphadenopathy. N Engl J Med 2008; 358:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/4\">",
"      Corcos D, Osborn MJ, Matheson LS. B-cell receptors and heavy chain diseases: guilty by association? Blood 2011; 117:6991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/5\">",
"      Haas IG, Wabl M. Immunoglobulin heavy chain binding protein. Nature 1983; 306:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/6\">",
"      Alexander A, Anicito I, Buxbaum J. Gamma heavy chain disease in man. Genomic sequence reveals two noncontiguous deletions in a single gene. J Clin Invest 1988; 82:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/7\">",
"      Hendershot L, Bole D, K&ouml;hler G, Kearney JF. Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein. J Cell Biol 1987; 104:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/8\">",
"      Prelli F, Frangione B. Franklin's disease: Ig gamma 2 H chain mutant BUR. J Immunol 1992; 148:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/9\">",
"      Wahner-Roedler DL, Witzig TE, Loehrer LL, Kyle RA. Gamma-heavy chain disease: review of 23 cases. Medicine (Baltimore) 2003; 82:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/10\">",
"      Husby G, Blichfeldt P, Brinch L, et al. Chronic arthritis and gamma heavy chain disease: coincidence or pathogenic link? Scand J Rheumatol 1998; 27:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/11\">",
"      FRANKLIN EC. STRUCTURAL STUDIES OF HUMAN 7S GAMMA-GLOBULIN (G IMMUNOGLOBULIN). FURTHER OBSERVATIONS OF A NATURALLY OCCURRING PROTEIN RELATED TO THE CRYSTALLIZABLE (FAST) FRAGMENT. J Exp Med 1964; 120:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/12\">",
"      Fermand JP, Brouet JC. Heavy-chain diseases. Hematol Oncol Clin North Am 1999; 13:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/13\">",
"      Wahner-Roedler DL, Kyle RA. Mu-heavy chain disease: presentation as a benign monoclonal gammopathy. Am J Hematol 1992; 40:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/14\">",
"      Agrawal S, Abboudi Z, Matutes E, Catovsky D. First report of fludarabine in gamma-heavy chain disease. Br J Haematol 1994; 88:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/15\">",
"      Preud'homme JL, Bauwens M, Dumont G, et al. Cast nephropathy in mu heavy chain disease. Clin Nephrol 1997; 48:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/16\">",
"      Kinoshita K, Yamagata T, Nozaki Y, et al. Mu-heavy chain disease associated with systemic amyloidosis. Hematology 2004; 9:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/17\">",
"      Zucker-Franklin D, Franklin EC. Ultrastructural and immunofluorescence studies of the cells associated with mu-chain disease. Blood 1971; 37:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12470/abstract/18\">",
"      Yanai M, Maeda A, Watanabe N, et al. Successful treatment of mu-heavy chain disease with fludarabine monophosphate: a case report. Int J Hematol 2004; 79:174.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6645 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-9F549ED38C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12470=[""].join("\n");
var outline_f12_11_12470=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      The normal immunoglobulin molecule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      The abnormal heavy chain in HCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Making the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Tissue diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Serum and urine studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ALPHA HCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GAMMA HCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MU HCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6645\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6645|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/2/1071\" title=\"figure 1\">",
"      Antibody structure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6645|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/54/876\" title=\"table 1\">",
"      CHOP chemotherapy NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=related_link\">",
"      Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7318?source=related_link\">",
"      Structure of immunoglobulins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_11_12471="Lymphedema stageI AB";
var content_f12_11_12471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphedema stage I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 446px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stage I lymphedema. A) Right lower extremity. B) Right upper extremity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tammy Mondry, DPT, MSRS, CLT-LANA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12471=[""].join("\n");
var outline_f12_11_12471=null;
var title_f12_11_12472="Carcinoid heart disease";
var content_f12_11_12472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Carcinoid heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12472/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12472/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12472/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12472/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12472/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12472/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/11/12472/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid tumors are rare, arising in 1.2 to 2.1 per 100,000 people in the general population per year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/1\">",
"     1",
"    </a>",
"    ]. They can arise anywhere in the body, but are most commonly found in the gastrointestinal tract (midgut carcinoids) and bronchus (foregut carcinoids) (",
"    <a class=\"graphic graphic_table graphicRef56015 \" href=\"UTD.htm?17/7/17531\">",
"     table 1",
"    </a>",
"    ). Primary midgut carcinoid tumors metastasize to the liver or regional lymph nodes and may present with bowel obstruction. In 20 to 30 percent of patients the initial presentation occurs as a result of hormone production, called the carcinoid syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common manifestations of the carcinoid syndrome are vasomotor changes (flushing) (",
"    <a class=\"graphic graphic_picture graphicRef55493 \" href=\"UTD.htm?15/40/16000\">",
"     picture 1",
"    </a>",
"    ), gastrointestinal hypermotility (secretory diarrhea), bronchospasm, and hypotension (",
"    <a class=\"graphic graphic_table graphicRef63079 \" href=\"UTD.htm?37/54/38763\">",
"     table 2",
"    </a>",
"    ). These symptoms are caused by the release of vasoactive substances, including serotonin (5-hydroxytryptamine), 5-hydroxytryptophan, histamine, bradykinin, tachykinins, and prostaglandins (",
"    <a class=\"graphic graphic_table graphicRef79329 \" href=\"UTD.htm?34/59/35771\">",
"     table 3",
"    </a>",
"    ). The diagnosis of carcinoid syndrome is usually suspected by the clinical features and confirmed by identification of the primary tumor, localization of metastatic lesions, and detection of increased urinary excretion of the by-product of serotonin metabolism, 5-hydroxyindoleacetic acid (5-HIAA) (",
"    <a class=\"graphic graphic_figure graphicRef51368 \" href=\"UTD.htm?12/15/12542\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Progress in the medical and surgical management of patients with carcinoid disease has resulted in improved symptoms and survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, carcinoid heart disease, which eventually occurs in over 50 percent of patients with carcinoid syndrome and may be the initial presentation of carcinoid disease in as many as 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], remains a major cause of morbidity and mortality among patients with carcinoid syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid heart disease is characterized by pathognomonic plaque-like deposits of fibrous tissue. These deposits occur most commonly on the endocardium of valvular cusps and leaflets, the cardiac chambers, and occasionally on the intima of the pulmonary arteries or aorta (",
"    <a class=\"graphic graphic_figure graphicRef74687 \" href=\"UTD.htm?29/32/30211\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/6\">",
"     6",
"    </a>",
"    ]. The valves and endocardium of the right side of the heart are most often affected [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], because inactivation of humoral substances by the lung protect the left heart (",
"    <a class=\"graphic graphic_picture graphicRef77192 \" href=\"UTD.htm?14/26/14755\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Left-sided valvular pathology occurs in less than 10 percent of patients with cardiac involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/2\">",
"     2",
"    </a>",
"    ]. It is almost always associated with an atrial right-to-left shunt (as with a patent foramen ovale) or a primary bronchial carcinoid [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. These abnormalities permit serotonin-rich blood to enter the left heart chambers without passing through the pulmonary capillaries. Infrequently, left-sided valve disease occurs in patients with severe, poorly controlled carcinoid syndrome with unusually high levels of circulating serotonin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The affected cardiac valves in carcinoid heart disease have a white appearance with thick leaflets and chordal structures. Microscopic examination demonstrates deposits of fibrous tissue. The carcinoid plaque is composed of smooth muscle cells, myofibroblasts, and an overlying endothelial cell layer. Smooth muscle cells and myofibroblasts are surrounded by an extracellular matrix composed of microfibrils, acid mucopolysaccharides, basement membrane, and collagen fibers. The morphology of the valve leaflet is not disrupted and the carcinoid plaque generally affects the ventricular aspect of the tricuspid valve leaflets and the arterial aspect of the pulmonic valve cusps [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/6,9\">",
"     6,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retraction and fixation of the tricuspid leaflets results in reduced motion and lack of central coaptation. These changes characteristically cause severe tricuspid regurgitation and less often tricuspid stenosis. The pulmonary valve is also commonly affected and may be regurgitant or stenotic. Right sided endocardial disease can occur in patients with advanced disease.",
"   </p>",
"   <p>",
"    An additional rare cardiac complication is metastasis to the heart. In a review of 11 such patients, the small bowel was the source in nine and all had the carcinoid syndrome and hepatic metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/4\">",
"     4",
"    </a>",
"    ]. Transthoracic echocardiography detected nine tumors &ge;1.0 cm in size in five of eleven patients, revealing a well circumscribed, noninfiltrating, and homogeneous mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Role of serotonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is thought that high circulating concentrations of serotonin are the major effector of carcinoid heart disease and of the similar valve lesions that may be induced by the ergot-alkaloid derivatives or the anorectic drugs fenfluramine (alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    ) and dexfenfluramine. The data supporting the role of serotonin in the pathogenesis of valve disease is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1528?source=see_link&amp;anchor=H2#H2\">",
"     \"Valvular heart disease induced by drugs\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indirect evidence in support of the role of serotonin in the carcinoid syndrome in humans comes from a study that compared 19 patients with carcinoid heart disease (diagnosed by echocardiography or cardiac catheterization) to 585 carcinoid patients without heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/10\">",
"     10",
"    </a>",
"    ]. The patients with heart disease had much higher (two to fourfold) values for serum and plasma serotonin, platelet serotonin, and urinary 5-HIAA excretion. They were also three times as likely to have typical carcinoid symptoms.",
"   </p>",
"   <p>",
"    Others note similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In one report in 23 patients with carcinoid syndrome, urinary 5-HIAA values averaged 356",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in those with heart disease compared to only 99",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in those without cardiac involvement",
"   </p>",
"   <p>",
"    Urinary 5-HIAA excretion may also predict progression of carcinoid heart disease. In a report from the Mayo Clinic, which included 71 patients in whom serial echocardiograms were performed more than one year apart, a \"cardiac score\" was developed to define the severity of cardiac involvement (including grading scales for tricuspid and pulmonic valve abnormalities as well as right ventricular size and function). Urinary 5-HIAA levels were significantly higher in those with a &gt;25 percent increase in cardiac score than in those with lesser evidence of progression (265 versus 189",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver disease, usually due to hepatic metastases, is thought to play a permissive role by allowing large quantities of tumor products such as serotonin to reach the right heart without being inactivated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Rarely, patients with a primary ovarian carcinoid develop carcinoid heart disease in the absence of hepatic metastases because the liver is bypassed by direct venous drainage of the ovary into the inferior vena cava [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence suggests a role for serotonin in the pathogenesis of carcinoid heart disease. Alterations in serotonin metabolism, its associated receptors and transporter gene have been proposed as likely mechanisms for development of carcinoid related valvular heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. However, it is not known if medical therapy to reduce serotonin secretion can prevent the development of cardiac lesions. In an uncontrolled observational series, patients treated with somatostatin analogs, which decrease serotonin secretion, did not prevent or delay valve disease. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Antitumor therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of carcinoid heart disease are often subtle early in the course of the disease. In addition, moderate to severe tricuspid and pulmonary valve disease may be well tolerated for many months. Early symptoms of right-sided valvular heart disease include fatigue and dyspnea on exertion. Right-sided heart failure with worsening dyspnea, edema, ascites and eventual cardiac cachexia occur with progressive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major findings on physical examination include an elevated jugular venous pressure, palpable right ventricular impulse and murmurs of tricuspid and pulmonary valve regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/20\">",
"     20",
"    </a>",
"    ]. Less frequently, a systolic murmur of pulmonary stenosis or a diastolic murmur of tricuspid stenosis is audible. Right-sided cardiac murmurs are accentuated by inspiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The auscultatory findings may be subtle, as the murmurs of tricuspid and pulmonary valve disease may be difficult to detect due to the low pressure in the pulmonary circulation. As an example, the murmur of pulmonic insufficiency in the absence of pulmonary hypertension does not have the high-pitched, blowing quality heard with higher pulmonary pressures. In such patients, elevation of the jugular venous pressure with a prominent \"v\" wave is often the earliest finding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"     \"Examination of the jugular venous pulse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As the valve disease progresses the physical features become readily apparent with progressive peripheral edema, ascites and pulsatile hepatomegaly. Highly aggressive carcinoid may cause relatively acute severe tricuspid regurgitation. The clinical picture and hemodynamics then can mimic those of constrictive pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/149?source=see_link\">",
"     \"Etiology, clinical features, and evaluation of tricuspid regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram in advanced carcinoid heart disease demonstrates low voltage QRS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/2\">",
"     2",
"    </a>",
"    ]. The cause of the low voltage is not clear but may be related to decreased conduction of the electrical signal to the body surface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest x-ray often demonstrates cardiomegaly with prominence of the right-sided cardiac chambers. Pulmonary congestion, if present, is mild. Pleural effusions and metastatic pleural plaque formation occur late in the course of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend a baseline echocardiogram in all patients with carcinoid syndrome. We repeat the echocardiogram in patients with clinical features of carcinoid heart disease or right heart failure.",
"   </p>",
"   <p>",
"    Characteristic echocardiographic features of advanced carcinoid heart disease include thickening and retraction of immobile tricuspid valve leaflets with associated tricuspid regurgitation, which is severe in 90 percent of patients (",
"    <a class=\"graphic graphic_movie graphicRef68261 \" href=\"UTD.htm?18/59/19381\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef56009 \" href=\"UTD.htm?7/41/7829\">",
"     movie 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/2\">",
"     2",
"    </a>",
"    ]. Less commonly, tricuspid valve stenosis is noted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14378?source=see_link\">",
"     \"Echocardiographic evaluation of the tricuspid valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary valve involvement usually coexists with tricuspid valve disease. The major finding on echocardiography is immobility of the pulmonary valve cusps. However, the pulmonary valve cusps may be difficult to visualize by echocardiography due to cusp retraction. Pulmonary annular constriction may also occur resulting in predominant pulmonary outflow tract obstruction.",
"   </p>",
"   <p>",
"    The frequency with which these and other findings occur was illustrated in a report in which echocardiography, including Doppler studies, was performed in 74 patients with carcinoid heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/2\">",
"     2",
"    </a>",
"    ]. The following distribution of lesions was noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients had tricuspid regurgitation, which was moderate to severe in 90 percent.",
"     </li>",
"     <li>",
"      Pulmonic stenosis was present in 53 percent, and some degree of pulmonic regurgitation was present in 81 percent.",
"     </li>",
"     <li>",
"      Left-sided valvular involvement was noted in five patients (7 percent), four of whom had a patent foramen ovale or carcinoid tumor involving the lung.",
"     </li>",
"     <li>",
"      A small pericardial effusion was seen in 14 percent; these effusions are rarely hemodynamically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-standing tricuspid and pulmonary valve disease results in progressive right ventricular volume overload and right ventricular diastolic pressure elevation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three-dimensional echocardiography may play an incremental role for the preoperative assessment of the pulmonary valve in patients with carcinoid heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     CMR and CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Features of carcinoid valve disease, including valve pathology and right ventricular size and function, can be evaluated by cardiovascular magnetic resonance (CMR) or computed tomography (CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. These modalities may be particularly helpful for quantification of right ventricular volumes and ejection fraction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A preliminary study found that levels of chromogranin-A (CgA) and N-terminal pro-brain natriuretic peptide (NT-proBNP) were associated with the presence and severity of tricuspid regurgitation as a manifestation of carcinoid heart disease among patients with neuroendocrine tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/24\">",
"     24",
"    </a>",
"    ]. However, echocardiography remains the standard for detection and quantitation of tricuspid regurgitation in patients with carcinoid disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link&amp;anchor=H35#H35\">",
"     \"Natriuretic peptide measurement in heart failure\", section on 'N-terminal pro-BNP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Levels of CgA and NT-proBNP were also independently associated with overall mortality. Survival at five years was 81 percent in patients with normal CgA levels, 44 percent in those with elevated CgA but normal NT-proBNP levels, and 16 percent in those with elevations in both CgA and NT-proBNP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Without treatment, the median duration of survival with malignant carcinoid syndrome ranges from 12 to 38 months from the onset of systemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The major therapeutic modality in such patients consists of symptom control, usually with a somatostatin analog (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    ). Tumor removal is of limited value since patients with carcinoid syndrome typically have metastatic disease and chemotherapy has not had much success. As a result, more aggressive approaches, such as surgical debulking of the liver and hepatic artery embolization, are being evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carcinoid heart disease with advanced symptoms (NYHA class III or IV) portends a particularly poor prognosis and the median survival is only 11 months; most die within one year because of progressive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/27\">",
"     27",
"    </a>",
"    ]. Limited therapeutic options, other than surgery, are available for those patients with symptomatic right heart failure. Diuretics temporarily improve symptoms related to edema but result in a further reduction in left-sided cardiac output, which in turn worsens fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antitumor therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of the tumor itself does not typically result in regression of valvular disease, as illustrated by the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/2,12,14\">",
"     2,12,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 23 patients, serial echocardiography was used to examine the association of urinary 5-HIAA excretion with the appearance or worsening of valvular lesions after treatment with a somatostatin analog, presumably",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/12\">",
"       12",
"      </a>",
"      ]. Despite major declines in 5-HIAA excretion in most patients, existing valvular lesions did not regress. However, the post-treatment levels of 5-HIAA independently predicted the development or progression of valvular abnormalities, with a threshold of about 100",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      In the report of 71 patients from the Mayo Clinic cited above, all patients received treatment with a somatostatin analogue, hepatic dearterialization,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/14\">",
"       14",
"      </a>",
"      ]. None of these therapies, which had a variable effect on urinary 5-HIAA excretion, were associated with a reduction in the risk of progressive valvular disease; to the contrary, chemotherapy was statistically correlated with a higher rate of progression, possibly because this form of therapy is typically reserved for patients with more aggressive carcinoid tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rarely, an ovarian carcinoid tumor can cause carcinoid heart disease without liver metastases. Such tumors have different implications for therapy. Because the ovarian veins bypass the portal circulation and enter the systemic venous circulation directly, cardiac involvement can occur without liver metastases. Tumor resection in such patients can be curative [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/17\">",
"     17",
"    </a>",
"    ]. Even in such cases, however, the cardiac manifestations do not typically regress after curative surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac surgery is the only effective treatment for carcinoid heart disease and should be considered for symptomatic patients whose metastatic carcinoid disease and symptoms of carcinoid syndrome are well controlled. Indications for surgical consideration include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired exercise capacity",
"     </li>",
"     <li>",
"      Progressive fatigue",
"     </li>",
"     <li>",
"      Progressive decline in right ventricular function in the presence of controlled metastatic carcinoid disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tricuspid valve replacement is the operation of choice in such cases. When pulmonary valve disease is present, valve replacement is preferable to valve resection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/29\">",
"     29",
"    </a>",
"    ]; double valve replacement can be undertaken simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/30\">",
"     30",
"    </a>",
"    ]. Balloon valvuloplasty is not recommended for pulmonic stenosis because of the coexistence of tricuspid and pulmonary valve regurgitation. Some patients require multivalve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical resection of metastases to the myocardium can be performed if only one or two such lesions are present [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with severe unoperated carcinoid cardiac disease are not candidates for hepatic surgery due to the risk of hepatic hemorrhage, induced by the elevated right-sided pressures, at the time of surgery. In occasional patients, cardiac surgical intervention is carried out despite minimal cardiac symptoms, in anticipation of hepatic surgical resection of metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691406#H691406\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early diagnosis of carcinoid heart disease and regular clinical follow-up of patients with valve disease helps determine the most appropriate timing of surgical intervention. Cardiac follow-up should include clinical examination, echocardiography, and exercise testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Choice of valve prosthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of valve prosthesis requires meticulous discussion and individual selection in patients with carcinoid heart disease. With the use of bioprosthetic valves, premature degeneration may be induced by the carcinoid process [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. The risk of valve degeneration may be offset by aggressive carcinoid tumor intervention and somatostatin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/27,30\">",
"     27,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mechanical prostheses are not ideal for patients with carcinoid heart disease since subsequent surgical procedures for tumor control are often required and are complicated by anticoagulation management. In addition the risk of mechanical tricuspid prosthesis thrombosis is about 4 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Anesthesia management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anesthesia can precipitate carcinoid crisis in patients with carcinoid syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. This syndrome, which is characterized by profound flushing, extreme changes in blood pressure, bronchoconstriction, arrhythmias, and confusion or stupor, can be fatal. Thus, control of carcinoid symptoms by an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    analog should be attained prior to anesthesia and meticulous anesthetic care is required during the procedure. Large doses of somatostatin are often required in the perioperative and postoperative periods [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948942#H190948942\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Prevention and management of carcinoid crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac surgery has been successful in reducing or relieving the cardiac symptoms of many patients with carcinoid heart disease. However, a 1995 review of a small surgical series from the Mayo Clinic noted a high surgical mortality and incomplete symptom resolution among surgical survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/27\">",
"     27",
"    </a>",
"    ]. In this study the outcome of 26 patients who underwent valve surgery was compared to 40 medically treated patients. The operative mortality was 35 percent, due primarily to postoperative bleeding and right heart failure. A high perioperative mortality was noted by others in this time period [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the 17 surgical survivors, eight were alive at a mean of 28 months. Late deaths were primarily due to liver dysfunction from metastases. There was marked symptomatic improvement in the eight long-term survivors. It was suggested that surgical intervention is the only definitive treatment and that the outcome might be better if surgery were performed before symptoms became severe.",
"   </p>",
"   <p>",
"    Cardiac surgery was primarily performed on patients with advanced right heart failure manifested by edema and ascites. Despite the high surgical mortality, the survival among surgically treated patients was better than that in medically treated patients with similar symptoms.",
"   </p>",
"   <p>",
"    Subsequent data from the Mayo Clinic found improved outcomes and a substantial reduction in surgical mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12472/abstract/42\">",
"     42",
"    </a>",
"    ]. In this series of 200 patients seen over 20 years, the patients were grouped by time of diagnosis: group A 1981 to 1989; group B 1989 to 1995; and group C 1995 to 2000. Most patients had heart failure at diagnosis and there was no difference in severity of tricuspid valve disease at first echocardiography in the three groups.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Median survival was significantly lower in group A compared to groups B and C (1.5 versus 3.2 and 4.4 years, respectively). The multivariate adjusted risk of mortality revealed a hazard ratio of 0.61 for group C compared to group A (95% CI 0.39-0.92).",
"     </li>",
"     <li>",
"      Among the 87 patients who underwent valve replacement (most New York Heart Association class III or IV) (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 4",
"      </a>",
"      ), postoperative mortality fell from 25 percent in group A to 9 percent in group C. When cardiac surgery was included as a time-dependent covariate in a multivariate analysis, it was associated with a significant risk reduction of 0.48 (95% CI 0.31-0.73).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It was suggested that the improvement in survival over time was related to valve replacement surgery as the frequency increased from 18 percent in group A to 48 percent in group B and 64 percent in group C. Over time, an increasing number of mildly symptomatic patients with severe valve dysfunction were offered surgery (NYHA class I or II 28 versus 8 percent in groups C and A) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other modalities used more frequently over time, such as somatostatin analogs for carcinoid syndrome and hepatic artery embolization or chemoembolization for hepatic metastases, improve symptoms but not survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential utility of chromogranin-A and N-terminal pro-brain natriuretic peptide levels to predict survival is discussed above (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Biomarkers'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carcinoid heart disease eventually occurs in over 50 percent of patients with carcinoid syndrome and may be the initial presentation in up to 20 percent of patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carcinoid heart disease is a rare form of heart disease characterized by plaque-like deposits of fibrous tissue, most frequently affecting the right heart valves and endocardium. Left-sided valve disease occurs in less than 10 percent of patients with cardiac involvement and is almost always associated with an atrial right-to-left shunt (as with a patent foramen ovale) or a primary bronchial carcinoid. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carcinoid heart disease most commonly causes tricuspid regurgitation. The pulmonary valve is commonly regurgitant or stenotic. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence suggests a role for serotonin in the pathogenesis of carcinoid heart disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Role of serotonin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of carcinoid heart disease are often subtle early in the course of the disease. Symptoms range from fatigue and dyspnea on exertion to edema, ascites, and eventual cardiac cachexia with progressive disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major findings of carcinoid heart disease on physical examination include an elevated jugular venous pressure, palpable right ventricular impulse, and murmurs of tricuspid and pulmonary valve regurgitation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A baseline echocardiogram is recommended in all patients with carcinoid syndrome. A follow-up echocardiogram is indicated in patients with clinical features of carcinoid heart disease or right heart failure. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carcinoid heart disease with advanced symptoms (NYHA class III or IV) portends a poor prognosis and the median survival is only 11 months. Patients with symptomatic right heart failure have limited therapeutic options other than surgery. Diuretics temporarily improve symptoms related to edema but result in a further reduction in left-sided cardiac output, which in turn worsens fatigue. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac surgery (tricuspid valve replacement and pulmonary valve replacement in patients with pulmonary valve disease) is the only effective treatment for carcinoid heart disease and should be considered for symptomatic patients whose metastatic carcinoid disease and symptoms of carcinoid syndrome are well controlled. Indications for surgical consideration include impaired exercise capacity, progressive fatigue, and progressive decline in ventricular function in the presence of controlled metastatic carcinoid disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cardiac surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In carcinoid patients with cardiac symptoms and controlled systemic disease, cardiac valve replacement surgery alleviates otherwise intractable symptoms and appears to improve survival. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cardiac surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early diagnosis and early surgical management of patients with carcinoid heart disease may provide the best results. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/1\">",
"      Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/2\">",
"      Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993; 87:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/3\">",
"      Lundin L, Norheim I, Landelius J, et al. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 1988; 77:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/4\">",
"      Westberg G, W&auml;ngberg B, Ahlman H, et al. Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg 2001; 88:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/5\">",
"      Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid heart disease. Circulation 2007; 116:2860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/6\">",
"      Pandya UH, Pellikka PA, Enriquez-Sarano M, et al. Metastatic carcinoid tumor to the heart: echocardiographic-pathologic study of 11 patients. J Am Coll Cardiol 2002; 40:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/7\">",
"      Roberts WC. A unique heart disease associated with a unique cancer: carcinoid heart disease. Am J Cardiol 1997; 80:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/8\">",
"      Mansencal N, Mitry E, Forissier JF, et al. Assessment of patent foramen ovale in carcinoid heart disease. Am Heart J 2006; 151:1129.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/9\">",
"      Connolly HM, Schaff HV, Mullany CJ, et al. Surgical management of left-sided carcinoid heart disease. Circulation 2001; 104:I36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/10\">",
"      Simula DV, Edwards WD, Tazelaar HD, et al. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc 2002; 77:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/11\">",
"      Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995; 92:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/12\">",
"      Denney WD, Kemp WE Jr, Anthony LB, et al. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol 1998; 32:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/13\">",
"      Zuetenhorst JM, Bonfrer JM, Korse CM, et al. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 2003; 97:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/14\">",
"      M&oslash;ller JE, Connolly HM, Rubin J, et al. Factors associated with progression of carcinoid heart disease. N Engl J Med 2003; 348:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/15\">",
"      Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983; 1:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/16\">",
"      Wilkowske MA, Hartmann LC, Mullany CJ, et al. Progressive carcinoid heart disease after resection of primary ovarian carcinoid. Cancer 1994; 73:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/17\">",
"      Chaowalit N, Connolly HM, Schaff HV, et al. Carcinoid heart disease associated with primary ovarian carcinoid tumor. Am J Cardiol 2004; 93:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/18\">",
"      Roth BL. Drugs and valvular heart disease. N Engl J Med 2007; 356:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/19\">",
"      Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet 2009; 374:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/20\">",
"      Ross EM, Roberts WC. The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med 1985; 79:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/21\">",
"      Lee KJ, Connolly HM, Pellikka PA. Carcinoid pulmonary valvulopathy evaluated by real-time 3-dimensional transthoracic echocardiography. J Am Soc Echocardiogr 2008; 21:407.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/22\">",
"      Bastarrika G, Cao MG, Cano D, et al. Magnetic resonance imaging diagnosis of carcinoid heart disease. J Comput Assist Tomogr 2005; 29:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/23\">",
"      Mollet NR, Dymarkowski S, Bogaert J. MRI and CT revealing carcinoid heart disease. Eur Radiol 2003; 13 Suppl 6:L14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/24\">",
"      Korse CM, Taal BG, de Groot CA, et al. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol 2009; 27:4293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/25\">",
"      Hajdu SI, Winawer SJ, Myers WP. Carcinoid tumors. A study of 204 cases. Am J Clin Pathol 1974; 61:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/26\">",
"      Godwin JD 2nd. Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975; 36:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/27\">",
"      Connolly HM, Nishimura RA, Smith HC, et al. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol 1995; 25:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/28\">",
"      Robboy SJ, Norris HJ, Scully RE. Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases. Cancer 1975; 36:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/29\">",
"      Connolly HM, Schaff HV, Mullany CJ, et al. Carcinoid heart disease: impact of pulmonary valve replacement in right ventricular function and remodeling. Circulation 2002; 106:I51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/30\">",
"      Voigt PG, Braun J, Teng OY, et al. Double bioprosthetic valve replacement in right-sided carcinoid heart disease. Ann Thorac Surg 2005; 79:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/31\">",
"      Arghami A, Connolly HM, Abel MD, Schaff HV. Quadruple valve replacement in patients with carcinoid heart disease. J Thorac Cardiovasc Surg 2010; 140:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/32\">",
"      McDonald ML, Nagorney DM, Connolly HM, et al. Carcinoid heart disease and carcinoid syndrome: successful surgical treatment. Ann Thorac Surg 1999; 67:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/33\">",
"      DiSesa VJ, Mills RM Jr, Collins JJ Jr. Surgical management of carcinoid heart disease. Chest 1985; 88:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/34\">",
"      Ridker PM, Chertow GM, Karlson EW, et al. Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease. Am Heart J 1991; 121:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/35\">",
"      Schoen FJ, Hausner RJ, Howell JF, et al. Porcine heterograft valve replacement in carcinoid heart disease. J Thorac Cardiovasc Surg 1981; 81:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/36\">",
"      Thorburn CW, Morgan JJ, Shanahan MX, Chang VP. Long-term results of tricuspid valve replacement and the problem of prosthetic valve thrombosis. Am J Cardiol 1983; 51:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/37\">",
"      Mason RA, Steane PA. Carcinoid syndrome: its relevance to the anaesthetist. Anaesthesia 1976; 31:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/38\">",
"      Caplin ME, Buscombe JR, Hilson AJ, et al. Carcinoid tumour. Lancet 1998; 352:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/39\">",
"      Vaughan DJ, Brunner MD. Anesthesia for patients with carcinoid syndrome. Int Anesthesiol Clin 1997; 35:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/40\">",
"      Weingarten TN, Abel MD, Connolly HM, et al. Intraoperative management of patients with carcinoid heart disease having valvular surgery: a review of one hundred consecutive cases. Anesth Analg 2007; 105:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/41\">",
"      Robiolio PA, Rigolin VH, Harrison JK, et al. Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol 1995; 75:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12472/abstract/42\">",
"      M&oslash;ller JE, Pellikka PA, Bernheim AM, et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 2005; 112:3320.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8135 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-5969107613-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12472=[""].join("\n");
var outline_f12_11_12472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Role of serotonin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CMR and CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Biomarkers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antitumor therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Choice of valve prosthesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Anesthesia management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8135\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8135|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/15/12542\" title=\"figure 1\">",
"      Tryptophan and serotonin metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/32/30211\" title=\"figure 2\">",
"      Plaques in carcinoid heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8135|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/40/16000\" title=\"picture 1\">",
"      Carcinoid flush",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/26/14755\" title=\"picture 2\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8135|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?18/59/19381\" title=\"movie 1\">",
"      Echocardiogram apical 4-chamber TV carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?7/41/7829\" title=\"movie 2\">",
"      TR four chamber color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8135|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/7/17531\" title=\"table 1\">",
"      Characteristics of carcinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/54/38763\" title=\"table 2\">",
"      Carcinoid symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/59/35771\" title=\"table 3\">",
"      Products of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 4\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14378?source=related_link\">",
"      Echocardiographic evaluation of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/149?source=related_link\">",
"      Etiology, clinical features, and evaluation of tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1528?source=related_link\">",
"      Valvular heart disease induced by drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_11_12473="Diagnosis and management of congenital anomalies of the vagina";
var content_f12_11_12473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and management of congenital anomalies of the vagina",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12473/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12473/contributors\">",
"     Marc R Laufer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12473/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12473/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12473/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12473/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/11/12473/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of the female genital tract is a complex process dependent upon a series of events involving cellular differentiation, migration, fusion, and canalization. Failure of any one of these processes results in a congenital anomaly.",
"   </p>",
"   <p>",
"    The American Society for Reproductive Medicine classifies female reproductive tract anomalies according to six groups, based upon clinical presentation and prognosis for fetal salvage upon treatment (",
"    <a class=\"graphic graphic_table graphicRef76124 \" href=\"UTD.htm?2/32/2572\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/1\">",
"     1",
"    </a>",
"    ]. This classification scheme does not include nonuterine anomalies, but permits additional descriptions of associated vaginal, tubal, and urinary abnormalities.",
"   </p>",
"   <p>",
"    Congenital anomalies of the vagina will be reviewed here. Congenital cervical and uterine anomalies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=see_link\">",
"     \"Congenital cervical anomalies and benign cervical lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of the female genital tract begins at three weeks of gestation and continues into the second trimester of pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gonads",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadal development results from migration of primordial germ cells to the genital ridge. At five weeks, the gonads are identical in both sexes and capable of differentiating into either an ovary or testis. The type of gonad that will develop depends upon the chromosomal sex. The first sign of ovarian differentiation is the absence of Sertoli cells at 6 to 7 weeks of gestation; the ovarian primordial follicles are identifiable after 13.5 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=see_link\">",
"     \"Normal sexual differentiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;The female genital tract is derived from the m&uuml;llerian ducts, urogenital sinus, and vaginal plate. Initially during the indifferent stage, male and female embryos have both mesonephric (wolffian) and paramesonephric (m&uuml;llerian) ducts. The paired mesonephric ducts connect the mesonephric kidneys to the cloaca. At approximately five weeks, the ureteric bud, a dorsal outgrowth of the mesonephric duct, stimulates the differentiation of the metanephros. The metanephros eventually becomes the functional kidney, while the mesonephros degenerates at approximately 10 weeks of gestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16296?source=see_link&amp;anchor=H3#H3\">",
"     \"Prenatal diagnosis of renal agenesis\", section on 'Embryology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Uterus and fallopian tubes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The m&uuml;llerian ducts are first identifiable at approximately six weeks of gestation when they begin to elongate caudally and cross the metanephric ducts medially to meet in the midline. By the seventh week, the urorectal septum has developed and separates the rectum from the urogenital sinus. Around 12 weeks, the caudal portion of the m&uuml;llerian ducts fuse to form the uterovaginal canal, which inserts into the dorsal wall of the urogenital sinus at M&uuml;ller's tubercle. The two m&uuml;llerian ducts are initially composed of solid tissue and lie side by side. Subsequently, internal canalization of each duct produces two channels divided by a septum that is reabsorbed in a cephalad direction by 20 weeks. The cranial, unfused portions of the m&uuml;llerian ducts develop into the fimbria and fallopian tubes, while the caudal, fused portions form the uterus and upper vagina (",
"    <a class=\"graphic graphic_figure graphicRef54216 \" href=\"UTD.htm?8/57/9104\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vagina",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sinovaginal bulbs are two solid evaginations originating in the urogenital sinus at the distal aspect of the m&uuml;llerian tubercle. The sinovaginal bulbs proliferate into the caudal end of the uterovaginal canal to become a solid vaginal plate. The lumen of the lower vagina is then formed by degeneration of the central cells of this vaginal plate, which occurs in a cephalad direction. Canalization is complete by 20 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hymen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vaginal lumen is separated from the urogenital sinus by the hymenal membrane. The hymen usually ruptures before birth due to degeneration of the central epithelial cells. However, a thin fold of mucous membrane persists around the vaginal introitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple integrated steps are required for normal development of the female genital tract; several key points are worthy of emphasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The development of the gonads occurs independent from that of the genital tract; therefore, women with congenital uterovaginal anomalies may have normal ovaries with normal hormonal production.",
"     </li>",
"     <li>",
"      The formation of the reproductive tract is closely associated with the development of the urinary system, thus genital tract anomalies are often associated with anomalies of the kidneys, ureters, or bladder.",
"     </li>",
"     <li>",
"      Disruption of normal embryologic processes of the m&uuml;llerian ducts, such as agenesis, failure of lateral fusion, or failure of canalization, result in development of the various congenital anomalies of the female reproductive tract.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANOMALIES OF THE HYMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hymenal membrane consists of fibrous connective tissue attached to the vaginal wall. Hymenal anomalies are derived from incomplete degeneration of the central portion of the hymen. These anatomic variants include imperforate, microperforate, septate, and cribriform hymens (",
"    <a class=\"graphic graphic_figure graphicRef57977 \" href=\"UTD.htm?8/20/8514\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imperforate hymen",
"    </span>",
"    &nbsp;&mdash;&nbsp;An imperforate hymen is one of the most common obstructive lesions of the female genital tract (",
"    <a class=\"graphic graphic_picture graphicRef78094 \" href=\"UTD.htm?9/8/9346\">",
"     picture 1",
"    </a>",
"    ). At birth, infants may have a bulging introitus due to mucocolpos from vaginal secretions stimulated by maternal estradiol. If the diagnosis is not made in the newborn period and the hymen remains imperforate, the mucus will be reabsorbed and the child usually remains asymptomatic until menarche. At that time, the adolescent girl may present with a history of cyclic abdominal or pelvic pain and hematocolpos, which may give the hymenal membrane a bluish discoloration. Marked distension of the vagina may also result in back pain, pain with defection, or difficulties with urination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair of the hymen can be performed at any age; however, the repair is facilitated if the tissues have undergone estrogen stimulation. Therefore, surgery is ideal in the newborn, postpubertal, or premenarchal time periods. Surgical repair, performed under anesthesia, consists of an elliptical incision in the membrane close to the hymenal ring (",
"    <a class=\"graphic graphic_figure graphicRef77857 \" href=\"UTD.htm?33/60/34767\">",
"     figure 3",
"    </a>",
"    ) followed by evacuation of the obstructed material. Extra-hymenal tissue is excised using electrocautery to create a normal sized orifice and the vaginal mucosa is sutured to the hymenal ring using 3-0 or 4-0 vicryl or chromic suture to prevent adhesion and recurrence of the obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Incomplete hymenal fenestration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incomplete fenestration of the hymenal opening [microperforate, septate, or cribiform (",
"    <a class=\"graphic graphic_figure graphicRef57977 \" href=\"UTD.htm?8/20/8514\">",
"     figure 2",
"    </a>",
"    )] is often asymptomatic. Patients may seek gynecologic evaluation because of inability to insert tampons, douches, or vaginal creams, or because of difficulty with coitus. In addition, women with microperforate hymens may present with postmenstrual spotting or malodorous discharge due to partial obstruction and poor drainage. If the menstrual products are not fully evacuated from the vagina, the retained blood may become infected and lead to bilateral tuboovarian abscesses.",
"   </p>",
"   <p>",
"    Treatment of microperforate, septate, and cribriform hymens involves resection of the excess hymenal tissue to create a functional hymenal ring, as described above. The excess hymenal tissue is excised with the use of electrocautery and interrupted sutures are placed to reapproximate the tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ANOMALIES OF THE VAGINA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Transverse vaginal septum",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transverse vaginal septum results when there is failure of fusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    canalization of the urogenital sinus and m&uuml;llerian ducts, which occurs in approximately 1 in 30,000 to 1 in 80,000 women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/3\">",
"     3",
"    </a>",
"    ]. These septa may be located at various levels in the vagina (",
"    <a class=\"graphic graphic_figure graphicRef53442 \" href=\"UTD.htm?25/31/26111\">",
"     figure 4",
"    </a>",
"    ); approximately 46 percent are found in the upper vagina, 35 to 40 percent in the middle portion, and 15 to 20 percent in the lower vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/4\">",
"     4",
"    </a>",
"    ]. The septa are generally less than 1 centimeter in thickness and may have a small central or eccentric perforation (",
"    <a class=\"graphic graphic_figure graphicRef56204 graphicRef80278 graphicRef54407 \" href=\"UTD.htm?27/40/28294\">",
"     figure 5A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/5\">",
"     5",
"    </a>",
"    ]. The majority of transverse vaginal septums have a fenestration and are thus not completely obstructed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The external genitalia appear normal, but internally the vagina is shortened (a blind pouch if there is obstruction). Children may present with mucocolpos, whereas adolescents can develop hematocolpos (",
"    <a class=\"graphic graphic_figure graphicRef54683 \" href=\"UTD.htm?15/58/16289\">",
"     figure 6",
"    </a>",
"    ) or pyohematocolpos due to an ascending infection through the small perforation. A mass may be palpated above the examining finger on rectoabdominal examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Evaluation and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonographic or magnetic resonance (MR) imaging helps to define the location and thickness of the septum and to differentiate between a high septum and congenital absence of the cervix.",
"   </p>",
"   <p>",
"    A small septum can be resected, followed by an end-to-end anastomosis of the upper and lower vaginal mucosa. A thick septum is more difficult to excise and repair; excision should be attempted only by surgeons experienced with this procedure. Reanastomosis is easier if the upper vagina has been distended with menstrual blood products, as this acts as a natural tissue expander to increase the amount of upper vaginal tissue available for the reanastomosis. In addition, preoperative use of vaginal dilators may thin the septum and facilitate reanastomosis. A Z-plasty technique can be used to prevent circumferential scar formation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=see_link\">",
"     \"Z-plasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 36 pregnancies have been reported in women with transverse septa. One-half had planned cesarean delivery, most of the rest had incision or instrumental dilation during labor, and a few underwent incision before pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/7\">",
"     7",
"    </a>",
"    ]. Outcomes were generally good.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Longitudinal vaginal septum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longitudinal septa are typically associated with uterine anomalies, such as septate uterus and uterus didelphys [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/8\">",
"     8",
"    </a>",
"    ]. The septum that divides the vagina may be partial or complete. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient may note difficulty inserting tampons, persistent bleeding despite tampon placement, dyspareunia, or she may be asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment involves complete removal of the septum. Excision is the traditional procedure with care to avoid compromise to the bladder and rectum. The septal tissue should be excised in total as retained fragments of septum may cause dyspareunia. The septal tissue is resected and then the normal vaginal mucosas from each vagina are sutured together over the defect created by the resection. Surgery is not required in asymptomatic women with a longitudinal vaginal septum, but will facilitate vaginal delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Obstructed hemi-vagina",
"    </span>",
"    &nbsp;&mdash;&nbsp;An obstructed hemi-vagina is usually associated with ipsilateral renal agenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient may have pain, pus from microcommunication from the obstructed side to the non-obstructed vagina, and rarely cyclic peritonitis. The diagnosis can be made by history and physical examination, combined with appropriate imaging (typically magnetic resonance imaging); laparoscopy is usually unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with an obstructed hemi-vagina require surgical correction due to pain, increased risk of infection, and retrograde menses. The obstructed vagina is entered, the fluid is drained, and then the vaginal tissue between the two vaginas is resected. Great care is taken to avoid the bladder, rectum and the cervixes. The two cervixes may be at different levels; therefore, the tissue between them should be left in place so as not to compromise their blood supply. The surgery can be performed as a single operation; alternatively, some surgeons prefer to drain the obstructed vagina by the creation of a \"window\" with a second operation performed at a later time after the inflammation and distention have resolved. We have found that in the vast majority of patients this anomaly can be surgically corrected in one operation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Vaginal agenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal agenesis, also known as m&uuml;llerian aplasia or Mayer-Rokitansky-K&uuml;ster-Hauser (MRKH) syndrome, refers to congenital absence of the vagina with variable uterine development. It results from agenesis or hypoplasia of the m&uuml;llerian duct system, although the underlying etiology remains unknown. Animal models have demonstrated that the WNT4 gene suppresses male sexual differentiation and ovarian androgen production [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/10\">",
"     10",
"    </a>",
"    ]. A loss of function mutation in this gene was reported in a 46,XX woman with bilateral ovaries, primary amenorrhea (due to mullerian agenesis), and hyperandrogenemia, suggesting that WNT4 may play a role in normal female sexual development [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly cited incidence for vaginal agenesis is 1 in 5000 (range 1 per 4000 to 10,000 females) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/12\">",
"     12",
"    </a>",
"    ]. It is usually accompanied by cervical and uterine agenesis; however, 7 to 10 percent of women have a normal but obstructed or rudimentary uterus with functional endometrium (",
"    <a class=\"graphic graphic_figure graphicRef69536 \" href=\"UTD.htm?32/62/33774\">",
"     figure 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef80263 \" href=\"UTD.htm?14/44/15055\">",
"     figure 8",
"    </a>",
"    ), while as many as 25 percent have cavitated m&uuml;llerian remnants [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. In one large series, ovaries were normal in 78 percent of affected patients, 16 percent had extra-pelvic ovaries, and 6 percent had unilateral hypoplastic ovaries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, these girls often exhibit extragenital anomalies. Approximately 25 to 50 percent have urologic anomalies, such as unilateral renal agenesis, pelvic or horseshoe kidneys, or irregularities of the collecting system [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/17-19\">",
"     17-19",
"    </a>",
"    ], and 10 to 15 percent have skeletal anomalies involving the spine, ribs, and extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/17,20\">",
"     17,20",
"    </a>",
"    ]. Other less common anomalies include congenital heart lesions, abnormalities of the hand, deafness, cleft palate, and inguinal or femoral hernias [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/17,21\">",
"     17,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genetics of MRKH are not known. Several studies in surrogacy programs have not demonstrated the defect in offspring of women with MRKH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;These women have a normal female karyotype with normal ovaries and ovarian function, thus they develop normal secondary sexual characteristics (eg, breast development, axillary hair, and public hair) except menarche does not occur. They often present with primary amenorrhea at 15 to 17 years of age. In fact, vaginal agenesis is the second most common cause of primary amenorrhea, after gonadal dysgenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/23\">",
"     23",
"    </a>",
"    ]. Most patients have a rudimentary nonfunctioning uterus, but 2 to 7 percent have a uterus with functioning endometrium and may present with cyclic or chronic abdominopelvic pain secondary to hematocolpos, hematometra, hematosalpinx, or endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On physical examination, the external genitalia are normal. A vaginal dimple or small pouch with a hymenal fringe is usually present, as the vaginal pouch and hymen are both derived from the urogenital sinus, not the m&uuml;llerian duct. Rectoabdominal examination is helpful for determining the presence or absence of midline structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound examination should be performed to assess the kidneys and confirm the presence of ovaries and the absence of a uterus. Urologic abnormalities (eg, pelvic kidney, duplicated ureters, ureteral diverticulum, bladder exstrophy) were noted in 47 percent of patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/19\">",
"     19",
"    </a>",
"    ]. Possible ureteral duplication can be determined by intravenous pyelography, if indicated. MR imaging may be useful for determining whether functional endometrium is present in a normal or rudimentary uterus.",
"   </p>",
"   <p>",
"    Differential diagnosis of vaginal agenesis includes androgen insensitivity, low-lying transverse vaginal septum, agenesis of the uterus and vagina. and imperforate hymen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Overview of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, there is no cross specialty (ie, gynecology, pediatric urology, pediatric surgery, plastic surgery) consensus on the ideal method for creation of a functional vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonsurgical treatment with self-dilatation recommended as first line for therapy by the American College of Obstetricians and Gynecologists [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/26\">",
"     26",
"    </a>",
"    ]. This non-surgical option is highly successful with excellent patient satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/27\">",
"     27",
"    </a>",
"    ]. A series of 69 patients with vaginal agenesis found that use of vaginal dilation achieved functional success in 88 percent of women at a median of 19 months. Functional success was defined as the ability to have sexual intercourse, vaginal acceptance of the largest dilator without discomfort or a vaginal length of 7 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery may be appropriate if nonsurgical therapy fails or, if after extensive counseling, a patient elects a surgical approach. The most commonly performed surgery by gynecologists is the McIndoe vaginoplasty, and data from over 1200 patients show a high success rate (92 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/29\">",
"     29",
"    </a>",
"    ]. Less invasive laparoscopic surgery, as in the Vecchietti procedure, seems promising; however, more data about results and long-term complications are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Ultimately, the best surgical option is dependent upon the experience of the attending surgeon and the woman's preference based upon the advantages and disadvantages of each procedure.",
"   </p>",
"   <p>",
"    The timing for nonsurgical and surgical creation of a vagina should be individualized to the patient. Treatment involves a combination of psychosocial support and correction of the anatomic abnormality. The psychologic aspects of a new diagnosis of vaginal agenesis can be overwhelming for any woman, especially an adolescent. Strong support and counseling and psychologic preparation before treatment play critical roles in the resolution of this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A normal sex life is possible after creation of a neovagina [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/26,33-35\">",
"     26,33-35",
"    </a>",
"    ]. Although the patient will be unable to carry a pregnancy, her eggs may be harvested for achieving pregnancy with a gestational carrier.",
"   </p>",
"   <p>",
"    Appropriate educational materials for the patient are very important. Updated patient information is available at",
"    <a class=\"external\" href=\"file://www.mrkh.org/\">",
"     www.mrkh.org",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.youngwomenshealth.org/\">",
"     www.youngwomenshealth.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Nonsurgical treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frank and Ingram procedures &mdash; A common nonoperative approach to creating a functional vagina uses vaginal dilators (ie, the Frank procedure or Ingram modification) and is highly successful [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/27,36,37\">",
"       27,36,37",
"      </a>",
"      ]. Graduated hard dilators are placed against the vaginal dimple and pressure is applied to progressively invaginate the mucosa. Initially, the smallest dilator (or a small pediatric blood drawing tube) is pressed firmly against the vaginal dimple daily for at least a half an hour after a warm bath. The adolescent should insert the tube downward and inward in the line of the normal vaginal axis and apply enough pressure to produce mild discomfort, but not pain. The time necessary time to create a vagina varies, ranging from four months up to several years, depending upon the patient's compliance. The Ingram modification of the Frank procedure involves the use of a bicycle seat mounted on a stool to create pressure for vaginal dilation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/38\">",
"       38",
"      </a>",
"      ]. Alternatively, repetitive coitus can also create a functional vagina [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/39\">",
"       39",
"      </a>",
"      ]. A review including 334 patients who underwent dilator therapy reported 86 percent were able to achieve satisfactory intercourse [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major advantage of a nonoperative approach is avoidance of surgery with its potential complications. However, some women feel very uncomfortable with the concept of using dilators and thus prefer surgical management. It is important to emphasize to them that although surgery can rapidly create a neovagina, many of the surgeries require the use of dilators postoperatively to maintain vaginal patency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Surgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is an option for women who have been unsuccessful with dilators or who prefer surgery after a thorough discussion of the advantages and disadvantages of the different techniques.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      McIndoe procedure &mdash; The McIndoe procedure, which is often used by gynecologists, utilizes a split-thickness skin graft from the buttocks [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/40\">",
"       40",
"      </a>",
"      ]. Use of artificial skin (Repliform&reg;) has been reported for this procedure, thus eliminating the need for a donor skin graft site [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/41\">",
"       41",
"      </a>",
"      ]. This skin graft is placed over a mold, dermal side out, and sewn together to form a tube with one closed end. A transverse incision is made at the vaginal dimple and a cavity is dissected to the level of the peritoneum. The mold and skin graft are then inserted and the labia minora are secured around the stent to prevent expulsion. The patient must remain on absolute bed rest and a low-residue diet (",
"      <a class=\"graphic graphic_table graphicRef51448 \" href=\"UTD.htm?17/2/17453\">",
"       table 2",
"      </a>",
"      ) for seven days, after which the stent is removed. Postoperatively, a vaginal dilator must be used continuously for three months and then at night for six additional months to prevent contraction of the vagina [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/42\">",
"       42",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients must be sufficiently motivated to comply with the strict postoperative regimens necessary to guarantee a successful procedure, thus timing surgery according to the individual's readiness for vaginal manipulation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intercourse is critical. Over 80 percent of patients report satisfactory sexual relationships and vaginal intercourse (ie, the functional success rate) after this surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/43-46\">",
"       43-46",
"      </a>",
"      ]. Complications, which occur in 5 to 10 percent of procedures, include graft failure, post-operative hematoma, rectal perforation, and fistula formation. The most important factor associated with a higher complication rate is a history of prior vaginal or perineal surgery.",
"     </li>",
"     <li>",
"      Williams vaginoplasty &mdash; The Williams vulvovaginoplasty involves the creation of a vaginal pouch. A horseshoe-shaped incision is made on the perineum and full-thickness skin flaps from the labia majora are used to create a kangaroo-like pouch, which is horizontal to the perineum [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/47\">",
"       47",
"      </a>",
"      ]. A vaginal dilator is then used daily for three to four weeks postoperatively. Although this technique is a simpler alternative to the McIndoe procedure, it is not usually performed as the vaginal pouch is only approximately 4 to 5 cm in length and positioned at an unusual angle for coitus [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/20,45\">",
"       20,45",
"      </a>",
"      ]. Modifications of this procedure that attempt to avoid these problems have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sigmoid vaginoplasty &mdash; Another option is to use a segment of sigmoid colon for vaginoplasty, a procedure performed by many pediatric surgeons [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. One end of the resected segment is pulled down to the introitus to form a neovagina, and the other end is closed to create a blind pouch. An end-to-end reanastomosis is performed to recreate a patent gastrointestinal tract. The advantage of this procedure over the McIndoe is that dilators are not needed. The disadvantages are that women complain of chronic vaginal discharge and foul odor. In addition, there is a risk of developing adenocarcinomas in these grafts [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/50,52\">",
"       50,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vecchietti procedure &mdash; Classically, the Vecchietti operation was an abdominal procedure performed through a Pfannenstiel skin incision [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/53\">",
"       53",
"      </a>",
"      ]; however, it has been modified to a laparoscopic approach [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/54-56\">",
"       54-56",
"      </a>",
"      ]. There is limited data about this relatively new technique [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/55\">",
"       55",
"      </a>",
"      ]. In a retrospective case series, at one year postoperatively, 98 percent of patients reported functional success [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/30\">",
"       30",
"      </a>",
"      ]. Vaginoscopic examination of patients up to 12 months after the laparoscopic Vecchietti operation revealed neovaginal mucosae comparable to normal vaginal mucosa [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The procedure involves creation of a neovagina by invagination using an acrylic \"olive\" that is placed against the vaginal dimple. This olive is attached to a traction device that rests on the abdomen by subperitoneal sutures placed laparoscopically. Sufficient traction is applied to the olive to produce 1.0 to 1.5 cm of invagination per day, thereby creating a neovagina in approximately 7 to 9 days. Once the neovagina has been created, active dilation is required until regular sexual activity is initiated.",
"   </p>",
"   <p>",
"    A prospective case series reported that a modification of technique (using blunt vaginoabdominal perforation of the vaginal dimple rather than sharp abdominovaginal dissection or tunneling of the vesicorectal space) and a new traction device significantly decreased operative time, perioperative complications and traction time, with a trend toward improvement in functional results [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One advantage of this technique over the Frank procedure is that uninterrupted traction is applied. In addition, prolonged hospitalization is not necessary as the traction can be completed as an outpatient. One study of 52 women reported 100 percent anatomic success and 98.1 percent functional success [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/54\">",
"     54",
"    </a>",
"    ]. However, this is a relatively new technique with limited data available [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Davydov procedure &mdash; Another laparoscopic approach is an adaptation of the Davydov procedure. The Davydov technique is a three stage surgery that includes dissection of the rectovesical space, abdominal mobilization of the peritoneum to create the vaginal fornices, and attachment of the peritoneum to the introitus [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/59\">",
"       59",
"      </a>",
"      ]. The laparoscopic approach closes the abdominal end of the neovagina with a purse-string suture. In one study, 27 of 324 women who underwent this procedure had laparoscopically-assisted surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/60\">",
"       60",
"      </a>",
"      ]. The success rates were similar for both the laparoscopically-assisted and traditional approaches; however, the laparoscopically assisted operation resulted in shorter operating times, lower intraoperative complications, shorter hospital stays, and no external scars. Postoperatively, sexual function (composite score for desire, arousal, lubrication, orgasm, satisfaction, pain) approaches that of matched controls without gynecological disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Agenesis of the lower vagina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absence of the lower vagina occurs as a result of abnormal development of the sinovaginal bulbs and vaginal plate (",
"    <a class=\"graphic graphic_figure graphicRef54407 \" href=\"UTD.htm?3/50/3887\">",
"     figure 5C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57905 \" href=\"UTD.htm?34/15/35071\">",
"     figure 9",
"    </a>",
"    ). The ovaries, uterus, cervix and upper vagina are normal, while the lower vagina is replaced by fibrous tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Clinical manifestations and evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents often present with primary amenorrhea accompanied by cyclic pelvic pain. A vaginal dimple may be noted on external inspection. Since these girls have normal cyclic pituitary-ovarian-endometrial function at menarche, the upper vagina will distend with blood products and secretions, which can be palpated as a mass on rectoabdominal examination. Ultrasound and MR imaging may be used to help define the presence of a uterus, cervix, and upper vagina.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment is surgical. The optimal timing of the procedure is when a large hematocolpos is present, as the distention helps to increase the amount of vaginal tissue available for a pull-through procedure.",
"   </p>",
"   <p>",
"    Initially, a transverse incision is made where the hymenal ring should be located. The dissection is carried out through the fibrous tissue until the upper vagina is reached and the obstruction can be drained. The vaginal mucosa is then identified and brought down to the introitus, where it is sutured to the hymenal ring. This permits normal sexual and reproductive function (",
"    <a class=\"graphic graphic_figure graphicRef60820 \" href=\"UTD.htm?30/57/31647\">",
"     figure 10",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Vaginal cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cysts from M&uuml;llerian remnants, epidermal inclusions, or Gartner's duct (wolffian remnant) usually form on the lateral or posterior vaginal walls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. A vaginal cysts may present in adolescence because of difficulty inserting a tampon or dyspareunia, but many are asymptomatic. Most can be treated by excision, although it may be safer to simply marsupialize deep cysts to avoid significant bleeding.",
"   </p>",
"   <p>",
"    Anterior wall masses may be vaginal wall cysts, but urethral diverticula are more common at this location. Other disorders that should be considered are leiomyoma, ectopic ureter, and vaginal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/63\">",
"     63",
"    </a>",
"    ]. In rare cases, a Gartner's duct cyst may communicate with an ectopic ureter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/64\">",
"     64",
"    </a>",
"    ]. For this reason, imaging of the urinary tract is indicated prior to excision of a vaginal wall mass in a patient with congenital urinary tract anomalies or unexplained leakage of urine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=see_link\">",
"     \"Urogenital tract fistulas in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Society for Reproductive Medicine classifies female reproductive tract anomalies according to six groups, based upon clinical presentation and prognosis for fetal salvage upon treatment (",
"      <a class=\"graphic graphic_table graphicRef76124 \" href=\"UTD.htm?2/32/2572\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12473/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of the gonads occurs independent from that of the genital tract; therefore, women with congenital uterovaginal anomalies may have normal ovaries with normal hormonal production. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Embryology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The formation of the reproductive tract is closely associated with the development of the urinary system, thus genital tract anomalies are often associated with anomalies of the kidneys, ureters, or bladder. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Embryology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery to repair hymenal symptomatic hymenal abnormalities is facilitated if the tissues have undergone estrogen stimulation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Anomalies of the hymen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common symptom associated with vaginal septa is difficulty with tampons or sexual intercourse. Imaging can help to delineate other reproductive tract anomalies occurring with a septum. Treatment is excision of the septum. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Transverse vaginal septum'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Longitudinal vaginal septum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Total vaginal agenesis is usually accompanied by cervical and uterine agenesis and urological anomalies. Ultrasound examination should be performed to assess the kidneys and confirm the presence of ovaries and the absence or presence of a uterus or uterine structures. Nonsurgical management is the preferred first line therapy for creation of a functional vagina; surgical treatment is also possible. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Vaginal agenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Agenesis/absence",
"      </span>",
"      of the lower vagina is usually associated with normal development of the ovaries, uterus, cervix and upper vagina. Imaging studies help to confirm the diagnosis. Treatment is surgical reconstruction. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Agenesis of the lower vagina'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cysts from M&uuml;llerian remnants, epidermal inclusions, or Gartner's duct usually form on the lateral or posterior vaginal walls. Anterior wall masses may be vaginal wall cysts, but urethral diverticula are more common at this location. Treatment of cysts is by excision or marsupialization. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Vaginal cysts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/1\">",
"      The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, m&uuml;llerian anomalies and intrauterine adhesions. Fertil Steril 1988; 49:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/2\">",
"      Voutilainen R. Differentiation of the fetal gonad. Horm Res 1992; 38 Suppl 2:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/3\">",
"      Rock JA, Azziz R. Genital anomalies in childhood. Clin Obstet Gynecol 1987; 30:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/4\">",
"      LODI A. [Clinical and statistical study on vaginal malformations at the Obstetrical and Gynecological Clinic in Milano, 1906-50]. Ann Ostet Ginecol 1951; 73:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/5\">",
"      Suidan FG, Azoury RS. The transverse vaginal septum: a clinicopathologic evaluation. Obstet Gynecol 1979; 54:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/6\">",
"      Garcia RF. Z-plasty for correction of congenital transferse vaginal septum. Am J Obstet Gynecol 1967; 99:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/7\">",
"      Blanton EN, Rouse DJ. Trial of labor in women with transverse vaginal septa. Obstet Gynecol 2003; 101:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/8\">",
"      Haddad B, Louis-Sylvestre C, Poitout P, Paniel BJ. Longitudinal vaginal septum: a retrospective study of 202 cases. Eur J Obstet Gynecol Reprod Biol 1997; 74:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/9\">",
"      Smith NA, Laufer MR. Obstructed hemivagina and ipsilateral renal anomaly (OHVIRA) syndrome: management and follow-up. Fertil Steril 2007; 87:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/10\">",
"      Vainio S, Heikkil&auml; M, Kispert A, et al. Female development in mammals is regulated by Wnt-4 signalling. Nature 1999; 397:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/11\">",
"      Biason-Lauber A, Konrad D, Navratil F, Schoenle EJ. A WNT4 mutation associated with M&uuml;llerian-duct regression and virilization in a 46,XX woman. N Engl J Med 2004; 351:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/12\">",
"      Evans TN, Poland ML, Boving RL. Vaginal malformations. Am J Obstet Gynecol 1981; 141:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/13\">",
"      Salvatore CA, Lodovicci O. Vaginal agenesis: an analysis of ninety cases. Acta Obstet Gynecol Scand 1978; 57:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/14\">",
"      Bates GW, Wiser WL. A technique for uterine conservation in adolescents with vaginal agenesis and a functional uterus. Obstet Gynecol 1985; 66:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/15\">",
"      Fedele L, Bianchi S, Frontino G, et al. Laparoscopic findings and pelvic anatomy in Mayer-Rokitansky-K&uuml;ster-Hauser syndrome. Obstet Gynecol 2007; 109:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/16\">",
"      Fedele L, Bianchi S, Frontino G, et al. Laparoscopically assisted uterovestibular anastomosis in patients with uterine cervix atresia and vaginal aplasia. Fertil Steril 2008; 89:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/17\">",
"      Griffin JE, Edwards C, Madden JD, et al. Congenital absence of the vagina. The Mayer-Rokitansky-Kuster-Hauser syndrome. Ann Intern Med 1976; 85:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/18\">",
"      Chawla S, Bery K, Indra KJ. Abnormalities of urinary tract and skeleton associated with congenital absence of vagina. Br Med J 1966; 1:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/19\">",
"      Fore SR, Hammond CB, Parker RT, Anderson EE. Urologic and genital anomalies in patients with congenital absence of the vagina. Obstet Gynecol 1975; 46:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/20\">",
"      Bergh, PA, Breen, JL, Gregori, CA. Congenital absence of the vagina &ndash; the Mayer-Rokitansky-K&uuml;ster-Hauser syndrome. Adoles Pediatr Gynecol 1989; 2:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/21\">",
"      Varner RE, Younger JB, Blackwell RE. M&uuml;llerian dysgenesis. J Reprod Med 1985; 30:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/22\">",
"      Petrozza JC, Gray MR, Davis AJ, Reindollar RH. Congenital absence of the uterus and vagina is not commonly transmitted as a dominant genetic trait: outcomes of surrogate pregnancies. Fertil Steril 1997; 67:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/23\">",
"      Reindollar RH, Byrd JR, McDonough PG. Delayed sexual development: a study of 252 patients. Am J Obstet Gynecol 1981; 140:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/24\">",
"      Murray JM, Gambrell RD Jr. Complete and partial vaginal agenesis. J Reprod Med 1979; 22:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/25\">",
"      Laufer MR. Congenital absence of the vagina: in search of the perfect solution. When, and by what technique, should a vagina be created? Curr Opin Obstet Gynecol 2002; 14:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/26\">",
"      ACOG Committee on Adolescent Health Care. ACOG Committee Opinion. Number 274, July 2002. Nonsurgical diagnosis and management of vaginal agenesis. Obstet Gynecol 2002; 100:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/27\">",
"      Jasonni VM, La Marca A, Naldi S, et al. The management of vaginal agenesis: report of 104 cases. Fertil Steril 2007; 88:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/28\">",
"      Gargollo PC, Cannon GM Jr, Diamond DA, et al. Should progressive perineal dilation be considered first line therapy for vaginal agenesis? J Urol 2009; 182:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/29\">",
"      Edmonds DK. Congenital malformations of the genital tract and their management. Best Pract Res Clin Obstet Gynaecol 2003; 17:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/30\">",
"      Borruto F, Camoglio FS, Zampieri N, Fedele L. The laparoscopic Vecchietti technique for vaginal agenesis. Int J Gynaecol Obstet 2007; 98:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/31\">",
"      Fedele L, Frontino G, Motta F, et al. Creation of a neovagina in Rokitansky patients with a pelvic kidney: comparison of long-term results of the modified Vecchietti and McIndoe techniques. Fertil Steril 2010; 93:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/32\">",
"      Bianchi S, Frontino G, Ciappina N, et al. Creation of a neovagina in Rokitansky syndrome: comparison between two laparoscopic techniques. Fertil Steril 2011; 95:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/33\">",
"      Hecker BR, McGuire LS. Psychosocial function in women treated for vaginal agenesis. Am J Obstet Gynecol 1977; 129:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/34\">",
"      Giannesi A, Marchiole P, Benchaib M, et al. Sexuality after laparoscopic Davydov in patients affected by congenital complete vaginal agenesis associated with uterine agenesis or hypoplasia. Hum Reprod 2005; 20:2954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/35\">",
"      MASTERS WH, JOHNSON VE. The artificial vagina: anatomic, physiologic, psychosexual function. West J Surg Obstet Gynecol 1961; 69:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/36\">",
"      Frank, RT. The formation of an artificial vagina without operation. Am J Obstet Gynecol 1938; 35:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/37\">",
"      Roberts CP, Haber MJ, Rock JA. Vaginal creation for m&uuml;llerian agenesis. Am J Obstet Gynecol 2001; 185:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/38\">",
"      Ingram JM. The bicycle seat stool in the treatment of vaginal agenesis and stenosis: a preliminary report. Am J Obstet Gynecol 1981; 140:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/39\">",
"      D'Alberton A, Santi F. Formation of a neovagina by coitus. Obstet Gynecol 1972; 40:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/40\">",
"      McINDOE A. The treatment of congenital absence and obliterative conditions of the vagina. Br J Plast Surg 1950; 2:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/41\">",
"      Kuohung W, Thompson SR, Laufer MR. Use of acellular human dermal allograft for vaginoplasty in Mayer-Rokitansky-K&uuml;ster-Hauser syndrome: a case report. J Reprod Med 2007; 52:864.",
"     </a>",
"    </li>",
"    <li>",
"     Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric &amp; Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Wolters Kluwer Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.188.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/43\">",
"      Rock JA, Reeves LA, Retto H, et al. Success following vaginal creation for M&uuml;llerian agenesis. Fertil Steril 1983; 39:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/44\">",
"      H&oslash;jsgaard A, Villadsen I. McIndoe procedure for congenital vaginal agenesis: complications and results. Br J Plast Surg 1995; 48:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/45\">",
"      Templeman CL, Lam AM, Hertweck SP. Surgical management of vaginal agenesis. Obstet Gynecol Surv 1999; 54:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/46\">",
"      Klingele CJ, Gebhart JB, Croak AJ, et al. McIndoe procedure for vaginal agenesis: long-term outcome and effect on quality of life. Am J Obstet Gynecol 2003; 189:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/47\">",
"      WILLIAMS EA. CONGENITAL ABSENCE OF THE VAGINA: A SIMPLE OPERATION FOR ITS RELIEF. J Obstet Gynaecol Br Commonw 1964; 71:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/48\">",
"      Creatsas G, Deligeoroglou E, Makrakis E, et al. Creation of a neovagina following Williams vaginoplasty and the Creatsas modification in 111 patients with Mayer-Rokitansky-K&uuml;ster-Hauser syndrome. Fertil Steril 2001; 76:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/49\">",
"      Wesley JR, Coran AG. Intestinal vaginoplasty for congenital absence of the vagina. J Pediatr Surg 1992; 27:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/50\">",
"      Pratt JH, Smith GR. Vaginal reconstruction with a sigmoid loop. Am J Obstet Gynecol 1966; 96:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/51\">",
"      Kapoor R, Sharma DK, Singh KJ, et al. Sigmoid vaginoplasty: long-term results. Urology 2006; 67:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/52\">",
"      Andryjowicz E, Qizilbash AH, DePetrillo AD, et al. Adenocarcinoma in a cecal neovagina--complication of irradiation: report of a case and review of literature. Gynecol Oncol 1985; 21:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/53\">",
"      Veronikis DK, McClure GB, Nichols DH. The Vecchietti operation for constructing a neovagina: indications, instrumentation, and techniques. Obstet Gynecol 1997; 90:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/54\">",
"      Fedele L, Bianchi S, Zanconato G, Raffaelli R. Laparoscopic creation of a neovagina in patients with Rokitansky syndrome: analysis of 52 cases. Fertil Steril 2000; 74:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/55\">",
"      Templeman C, Hertweck SP. Vaginal agenesis: an opinion on the surgical management. J Pediatr Adolesc Gynecol 2000; 13:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/56\">",
"      Fedele L, Busacca M, Candiani M, Vignali M. Laparoscopic creation of a neovagina in Mayer-Rokitansky-K&uuml;ster-Hauser syndrome by modification of Vecchietti's operation. Am J Obstet Gynecol 1994; 171:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/57\">",
"      Fedele L, Bianchi S, Berlanda N, et al. Neovaginal mucosa after Vecchietti's laparoscopic operation for Rokitansky syndrome: structural and ultrastructural study. Am J Obstet Gynecol 2006; 195:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/58\">",
"      Brucker SY, Gegusch M, Zubke W, et al. Neovagina creation in vaginal agenesis: development of a new laparoscopic Vecchietti-based procedure and optimized instruments in a prospective comparative interventional study in 101 patients. Fertil Steril 2008; 90:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/59\">",
"      Davydov, SN. Colpopoiesis from the peritoneum of the uterorectal space. Obstet Gynecol 1969; 12:55.",
"     </a>",
"    </li>",
"    <li>",
"     Adamyan LV. Laparoscopic management of vaginal aplasia with or without functional noncommunicating rudimentary uterus. In: Principles of Laparoscopic Surgery, Arrequi ME, Fitzgibbons RJ, Katkhouda N, McKernan JB, Reich H (Eds), Springer-Verlag, New York 1995. p.646.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/61\">",
"      Pradhan S, Tobon H. Vaginal cysts: a clinicopathological study of 41 cases. Int J Gynecol Pathol 1986; 5:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/62\">",
"      Wai CY, Corton MM, Miller M, et al. Multiple vaginal wall cysts: diagnosis and surgical management. Obstet Gynecol 2004; 103:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/63\">",
"      Blaivas JG, Flisser AJ, Bleustein CB, Panagopoulos G. Periurethral masses: etiology and diagnosis in a large series of women. Obstet Gynecol 2004; 103:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12473/abstract/64\">",
"      Dwyer PL, Rosamilia A. Congenital urogenital anomalies that are associated with the persistence of Gartner's duct: a review. Am J Obstet Gynecol 2006; 195:354.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5417 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12473=[""].join("\n");
var outline_f12_11_12473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gonads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Uterus and fallopian tubes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vagina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hymen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANOMALIES OF THE HYMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imperforate hymen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Incomplete hymenal fenestration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ANOMALIES OF THE VAGINA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Transverse vaginal septum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Evaluation and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Longitudinal vaginal septum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Obstructed hemi-vagina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Vaginal agenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Overview of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Nonsurgical treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Agenesis of the lower vagina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Vaginal cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5417\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5417|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/57/9104\" title=\"figure 1\">",
"      Uterine and vaginal development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/20/8514\" title=\"figure 2\">",
"      Hymen anatomic variations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/60/34767\" title=\"figure 3\">",
"      Hymenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/31/26111\" title=\"figure 4\">",
"      Locations transverse vag septa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/8/2176\" title=\"figure 5A\">",
"      Complete transverse vag septum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/42/33455\" title=\"figure 5B\">",
"      Transverse vaginal septum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/50/3887\" title=\"figure 5C\">",
"      Lower vaginal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/58/16289\" title=\"figure 6\">",
"      Hematocolpos",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/62/33774\" title=\"figure 7\">",
"      Vaginal agenesis rudiment horns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/44/15055\" title=\"figure 8\">",
"      Cervico-vaginal agenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/15/35071\" title=\"figure 9\">",
"      Agenesis lower vagina complete",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/57/31647\" title=\"figure 10\">",
"      Vaginal pull through procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5417|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/8/9346\" title=\"picture 1\">",
"      Imperforate hymen 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5417|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/32/2572\" title=\"table 1\">",
"      Types of Mullerian anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/2/17453\" title=\"table 2\">",
"      Dietary fiber in foods",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=related_link\">",
"      Clinical manifestations and diagnosis of congenital anomalies of the uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=related_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=related_link\">",
"      Normal sexual differentiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16296?source=related_link\">",
"      Prenatal diagnosis of renal agenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44792?source=related_link\">",
"      Urogenital tract fistulas in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=related_link\">",
"      Z-plasty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_11_12474="Maintenance immunosuppression following lung transplantation";
var content_f12_11_12474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Maintenance immunosuppression following lung transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12474/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12474/contributors\">",
"     Pamela J McShane, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12474/contributors\">",
"     Sangeeta Bhorade, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12474/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12474/contributors\">",
"     Elbert P Trulock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/11/12474/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/11/12474/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/11/12474/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H32759821\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance immunosuppressive therapy is administered to all lung transplant recipients to help prevent acute and chronic rejection and the loss of the lung allograft. [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/1\">",
"     1",
"    </a>",
"    ]. Substantial progress has been made in developing immunosuppressive regimens to prevent acute and chronic rejection, while trying to reduce the side effects of immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/2\">",
"     2",
"    </a>",
"    ]. However, despite improvements in immunosuppressive therapy, acute and chronic transplant rejection remain important obstacles to successful lung transplantation.",
"   </p>",
"   <p>",
"    The protocols for immunosuppressive therapy following lung transplantation can be divided into three general categories: induction, maintenance, and treatment of rejection. Strategies for maintenance of immunosuppression in the lung transplant recipient will be reviewed here. The role of induction agents in immunosuppression, general issues related to lung transplantation, the immunology of sold organ transplantation, and the diagnosis and treatment of acute and chronic lung transplant rejection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3688?source=see_link\">",
"     \"Induction immunosuppression following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3480?source=see_link\">",
"     \"Lung transplantation: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=see_link\">",
"     \"Evaluation and treatment of acute lung transplant rejection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32760008\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three general principles underlie immunosuppressive therapy following lung transplantation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first principle is that immune reactivity and the tendency toward graft rejection are highest early (within the first three to six months) after graft implantation and decrease with time. Thus, most regimens employ the highest intensity of immunosuppression immediately after surgery and decrease the intensity of therapy over the first year, eventually settling on the lowest maintenance levels of immunosuppression that are compatible with preventing graft rejection while minimizing drug toxicities.",
"     </li>",
"     <li>",
"      The second principle is to use low doses of several drugs with non-overlapping toxicities in preference over higher (and more toxic) doses of fewer drugs whenever feasible. Combination regimens are also better able to block the complex immunological cascade that leads to allograft rejection. &nbsp;",
"     </li>",
"     <li>",
"      The third principle is to avoid over-immunosuppression, because it leads to a myriad of undesirable effects including susceptibility to infection and malignancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"       \"Infection in the solid organ transplant recipient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"       \"Development of malignancy following solid organ transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"       \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no consensus regarding the optimal regimen for immunosuppression following lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, there are no immunosuppressive medications that are FDA approved for use in lung transplantation. Based on data from case series and clinical experience, we typically initiate maintenance immunosuppression with a combination of three drugs: a glucocorticoid (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ), a calcineurin inhibitor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ), and a nucleotide blocking agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef60918 \" href=\"UTD.htm?19/41/20127\">",
"     table 1",
"    </a>",
"    ). The mTOR inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    ) are the newest drugs to be used in lung transplantation maintenance immunosuppression and are being evaluated as alternatives to the nucleotide blocking agents.",
"   </p>",
"   <p>",
"    Many drugs used in immunosuppression are metabolized by the cytochrome P450 (CYP450) enzyme system in the liver. These, along with other drugs that induce and inhibit this enzyme system are listed in the table, along with suggestions for alternatives, additional monitoring, and dose adjustments (",
"    <a class=\"graphic graphic_table graphicRef81998 \" href=\"UTD.htm?14/44/15042\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32760049\">",
"    <span class=\"h1\">",
"     AGENTS FOR MAINTENANCE THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758258\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance therapy for lung transplantation has always included glucocorticoids. Glucocorticoids inhibit both humoral and cell-mediated immunity. The principle effect of glucocorticoids is to turn off gene transcription of multiple inflammatory genes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/3\">",
"     3",
"    </a>",
"    ]. The result is a decrease in the inflammatory response through reduced production of cytokines, interleukin (IL)-1, interleukin (IL)-2, interleukin (IL)-6, interferon (IFN)-gamma, and tumor necrosis factor (TNF)-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link&amp;anchor=H27#H27\">",
"     \"Transplantation immunobiology\", section on 'Molecular mechanisms of T-cell activation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical initial dose of glucocorticoid is administered perioperatively and is the equivalent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    500 to 1000 mg, administered intravenously (",
"    <a class=\"graphic graphic_table graphicRef60918 \" href=\"UTD.htm?19/41/20127\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/5\">",
"     5",
"    </a>",
"    ]. Subsequently,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is given orally at 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, or an equivalent dose intravenously; the relative potencies of the different glucocorticoid preparations are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef52276 \" href=\"UTD.htm?1/32/1547\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    is tapered to 5 to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    during the first year post lung transplant; in most patients, prednisone can be tapered to 5 mg per day by three months post transplant. Episodes of acute rejection are treated with high dose parenteral glucocorticoids, which are tapered back to the maintenance dose over several weeks. The majority of patients stay on prednisone for life, although a few patients are able to successfully wean off of it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation and treatment of acute lung transplant rejection\", section on 'High-dose glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoids are associated with a number of side effects including, but not limited to, diabetes, fluid retention, hypertension, emotional lability, poor wound healing, and susceptibility to infection. Efforts have been made to minimize glucocorticoid use in the lung transplantation population due to these side effects. However, very few attempts at complete glucocorticoid withdrawal have been successful [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758265\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcineurin inhibitors (CNIs) include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CsA) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (TAC). Calcineurin inhibitors are felt to be essential components of maintenance immunosuppression, and protocols without a calcineurin inhibitor are not recommended due to insufficient immunosuppression. However, the choices between tacrolimus or cyclosporine are felt to be up to the individual center [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/8-13\">",
"     8-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both CsA and TAC are used for maintenance immunosuppression; TAC has additional roles in recurrent acute rejection and in chronic rejection manifest as the bronchiolitis obliterans syndrome (BOS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation and treatment of acute lung transplant rejection\", section on 'Treatment of acute cellular rejection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link&amp;anchor=H19#H19\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758272\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CsA) was first demonstrated in lung transplantation in 1983 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. CsA was revolutionary in the field of organ transplantation because it was the first T-cell-selective drug [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/15\">",
"     15",
"    </a>",
"    ]. CsA binds to intracellular proteins (cyclophilin) that inhibit calcineurin, a protein phosphatase that is critical for T-cell activation. Through calcineurin inhibition, transcription of interleukin-2 (IL-2) and several other cytokines is inhibited. CsA, therefore, inhibits activation and proliferation of T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    Cyclosporine was included in the maintenance immunosuppression regimen in approximately 20 percent of lung transplantations performed between January 2002 and June 2009 (for a figure showing updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled Snapshot of maintenance immunosuppressive drug usage at:",
"    <a class=\"external\" href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\">",
"     file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, an initial dose of CsA of 2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is administered at the time of transplantation as a 24 hour infusion or half the dose as a 4 hour infusion twice a day and continued until the patient is able to take oral medication; dosing is adjusted per target concentrations (",
"    <a class=\"graphic graphic_table graphicRef60918 \" href=\"UTD.htm?19/41/20127\">",
"     table 1",
"    </a>",
"    ). The maintenance oral dose is 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice a day, orally as a tablet or a suspension.",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/cyclosporine-drug-information?source=see_link\">",
"     CsA",
"    </a>",
"    &nbsp;can be administered intravenously, for those unable to take oral medication. The intravenous dose is about 30 percent of the usual oral dose because of improved bioavailability and because it is given as a continuous infusion.",
"   </p>",
"   <p>",
"    Because CsA has significant inter and intraindividual absorption variability and a narrow therapeutic window, monitoring of drug levels is crucial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/18\">",
"     18",
"    </a>",
"    ]. Trough levels are targeted at 250 to 350",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    although they correlate poorly with the systemic effects of CsA. In lung transplantation patients, CsA levels drawn at two or three hours post dose (called C2 and C3, respectively) are highly predictive to estimate the exposure to CsA over time. The goal is to maintain the C2 levels between 900 and 1200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for the first year post transplant.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is cleared in the bile after extensive metabolism in the liver by CYP 3A4, and thus there are substantial drug-drug interactions with other medications metabolized via CYP 3A4 (",
"    <a class=\"graphic graphic_table graphicRef81998 \" href=\"UTD.htm?14/44/15042\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The original commercial preparation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , Sandimmune, has poor and unpredictable absorption due to its highly lipophilic nature and dependence on bile for absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/19\">",
"     19",
"    </a>",
"    ]. The newer, microemulsion formulation, Neoral (Novartis), has improved bioavailability, more consistent oral absorption, and more reproducible pharmacokinetic behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/20\">",
"     20",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    As a result, Neoral, Sandimmune, and generic formulations should not be used interchangeably and vigilant pharmacokinetic monitoring should accompany any change in formulation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal dysfunction is a common dose-related side effect and is a serious problem with long-term treatment. Other potential side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H17#H17\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758279\">",
"    <span class=\"h3\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (TAC, FK-506) was introduced in liver transplantation in 1989, and its use has now surpassed that of CsA in lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/2\">",
"     2",
"    </a>",
"    ]. TAC binds with the cytoplasmic immunophilin, FK binding protein 12 (FKBP-12) and inactivates calcineurin, thus inhibiting both interleukin-2 and interferon-gamma. Ultimately, T cell activation and proliferation are inhibited. TAC is more potent in its immunosuppressive properties than CsA, but is less nephrotoxic, possibly because it induces transforming growth factor beta (TGF-B1) to a lesser extent than CsA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual initial dose is 0.05 to 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 24 hours as a continuous infusion, starting within 6 hours post transplant. When the patient is able to take oral medication, the usual TAC dose is 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given every 12 hours, and adjusted as per blood levels. TAC may also be administered sublingually in patients who are unable to tolerate oral dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like CsA, TAC has poor oral absorption, variable bioavailability, and a narrow therapeutic window [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/16\">",
"     16",
"    </a>",
"    ]. To improve absorption, patients should take the drug on an empty stomach or two hours after a meal. Careful monitoring of blood levels is essential; the goal is to maintain serum trough levels between 5 and 15",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    The exact target level within this range depends on the clinical circumstances; the target level may be higher when there is evidence of allograft rejection or lower when there is TAC-related toxicity.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    is cleared in the bile after extensive metabolism in the liver by CYP 3A4, and thus there are substantial drug-drug interactions with other medications metabolized via CYP 3A4 (",
"    <a class=\"graphic graphic_table graphicRef81998 \" href=\"UTD.htm?14/44/15042\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal dysfunction is a common dose-related side effect and is a serious problem with long-term TAC treatment. In patients who develop renal insufficiency, calcineurin inhibitor levels should be reduced. Other potential side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H17#H17\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758286\">",
"    <span class=\"h3\">",
"     Tacrolimus versus cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on several small trials and our clinical experience, we suggest that initial maintenance immunosuppression regimens for lung transplantation include TAC rather than CsA. Supportive evidence comes from the studies outlined below that report a reduction in acute and chronic lung allograft rejection when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is used in the regimen instead of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    when the regimen includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (AZA). No statistically significant differences in survival were noted in these studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 133 lung transplant patients, fewer patients in the",
"      <span class=\"nowrap\">",
"       TAC/AZA/glucocorticoid",
"      </span>",
"      group developed bronchiolitis obliterans syndrome (BOS) compared with the",
"      <span class=\"nowrap\">",
"       CsA/AZA/glucocorticoid",
"      </span>",
"      group (21.7 versus 38 percent; p = 0.025) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective trial compared the efficacy of TAC versus CsA in 90 lung transplantation patients who also received AZA and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ; those treated with TAC were significantly less likely to develop acute rejection or lymphocytic bronchitis (41 versus 63 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the above studies, the benefit of TAC relative to CsA is less apparent when the drugs are coupled with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) instead of AZA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In an open trial, 74 lung transplant recipients, who received induction therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/36/2629?source=see_link\">",
"     rabbit antithymocyte globulin",
"    </a>",
"    (rATG), were randomly assigned to the combination of",
"    <span class=\"nowrap\">",
"     CsA/MMF/glucocorticoids",
"    </span>",
"    or the combination of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"      tacrolimus",
"     </a>",
"     /MMF/glucocorticoids",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/10\">",
"     10",
"    </a>",
"    ]. No significant difference was noted in the incidence of acute rejection or survival; a trend towards more infections was noted in the CsA group. Drug-related adverse effects were similar in number although different in type; hypertension was more common in the CsA group, while new-onset diabetes mellitus was more common in the TAC group.",
"   </p>",
"   <p>",
"    Taken together, these studies lean in favor of TAC and reflect clinical practice and registry outcome data. According to the 2009 Registry of the ISHLT, TAC was the predominant calcineurin inhibitor used in lung transplant recipients (64 percent at year one and 52 percent at year five post transplant) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758293\">",
"    <span class=\"h2\">",
"     Nucleotide blocking agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    are nucleotide blocking agents that are common agents in maintenance immunosuppression regimens following lung transplantation. The choice between mycophenolate and azathioprine is generally left to the individual center [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/2,5,25,26\">",
"     2,5,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758300\">",
"    <span class=\"h3\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) is a fermentation product of",
"    <em>",
"     Penicillium brevicompactum",
"    </em>",
"    and related fungi. After oral administration, MMF is rapidly absorbed and converted in the liver to its active form, mycophenolic acid (MPA). MPA depletes guanosine nucleotides in T and B lymphocytes, thus inhibiting proliferation of T and B cells and the glycosylation and expression of adhesion molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/5,27\">",
"     5,27",
"    </a>",
"    ]. Between January 2002 and June 2009, approximately 45 percent of lung transplant recipients received maintenance immunosuppression regimen containing MMF during their first post transplant year; slightly fewer were still receiving an MMF-containing regimen at five years post transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial dose of MMF is 250 mg twice a day, starting within 72 hours after transplantation. The dose is titrated up to a maximum dose of 500 to 1000 mg orally given twice daily. Dosing information is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef60918 \" href=\"UTD.htm?19/41/20127\">",
"     table 1",
"    </a>",
"    ). Due to potent myelosuppression, careful monitoring of complete blood counts should be performed on a regular basis. Other major side effects include diarrhea, nausea, and abdominal pain, but not nephrotoxicity.",
"   </p>",
"   <p>",
"    MMF is available as a capsule and as a powder for intravenous use after reconstitution; MPA (Myfortic) contains mycophenolic acid in a delayed release oral tablet. MPA has been found to be comparable in efficacy to the previous formulation of MMF in renal and cardiac transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The following conversions between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) and mycophenolate sodium should provide equimolar amounts of MPA:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1000 mg MMF = 720 mg MPA",
"     </li>",
"     <li>",
"      1500 mg MMF = 1080 mg MPA",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Monitoring of MMF serum levels is not routinely performed. There are, however, a number of drugs and agents that interact with MPA, including birth control pills, aluminum and magnesium antacids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=see_link&amp;anchor=H12#H12\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758307\">",
"    <span class=\"h3\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    (AZA) is an anti-metabolite that has been used in lung transplantation in combination with glucocorticoids since the 1960s. By preventing the de novo synthesis of purines and thus interfering with RNA and DNA synthesis, AZA inhibits the replication of T- and B-cells. In addition, AZA",
"    <sup>",
"    </sup>",
"    metabolites have been shown to turn the costimulatory signal",
"    <sup>",
"    </sup>",
"    CD28 into an apoptotic signal, resulting in lymphocyte depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Based on data from the ISHLT registry, AZA is included in the maintenance immunotherapy regimens of approximately 30 percent of adult lung transplantations performed between January 2002 and June 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AZA is metabolized to 6",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (6-MP) by glutathione, and then converted to 6-thiouric acid, 6 methyl-MP and 6-thioguanine (6TG) by thiopurine S-methyltransferase (TPMT). Approximately 10 percent of the population possesses a polymorphism of TPMT",
"    <strong>",
"    </strong>",
"    that causes low enzyme activity and potential acute AZA-induced myelosuppression. Some transplant centers assess TPMT levels at the time of listing for transplant, but this is not routine practice. AZA is avoided or used with caution in patients with known TPMT deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=see_link&amp;anchor=H9#H9\">",
"     \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AZA is typically initiated on the first day after transplantation at a dose of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day up to a maximum of 200 mg per day in a single dose, orally (",
"    <a class=\"graphic graphic_table graphicRef60918 \" href=\"UTD.htm?19/41/20127\">",
"     table 1",
"    </a>",
"    ). Bone marrow, liver, and pancreatic toxicity are potential side effects of AZA and require close monitoring as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef83298 \" href=\"UTD.htm?19/19/19773\">",
"     table 4",
"    </a>",
"    ). AZA should not be used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    due to decreased metabolism and increased drug toxicity. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758314\">",
"    <span class=\"h3\">",
"     Mycophenolate mofetil versus azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from other solid organ transplants support the use of MMF over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , but the literature in lung transplant has not been as definitively in favor of MMF. Nonetheless, MMF is used more frequently than AZA for maintenance immunosuppression following lung transplantation. Roughly two-thirds of maintenance immunosuppressive regimens included MMF at five years after transplantation according to the ISHLT registry (for a figure showing the use of the maintenance immunosuppression regimens, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled &ldquo;Snapshot of maintenance immunosuppressive drug usage at 1 and 5 years after adult lung transplantation&rdquo; at:",
"    <a class=\"external\" href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\">",
"     file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data comparing MMF and AZA are conflicting. Small case series have suggested superiority of MMF to AZA in preventing acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    However, two randomized trials comparing MMF to AZA in lung transplantation did not show a clear superiority of MMF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. One of these studies was a randomized, multicenter trial that compared MMF to AZA in 315 lung transplantation recipients in a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based regimen following anti-thymocyte globulin (ATG) induction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/26\">",
"     26",
"    </a>",
"    ]. At interim analysis, 12-month survival was better in the MMF group versus AZA (88.1 versus 79.1 percent, respectively p = 0.038). By three years, however, survival was not significantly different in the two groups. Additionally, the incidence of BOS and biopsy-proven acute rejection was not different between the two groups at the one year interim analysis or at three years. Infection and malignancy rates were likewise similar in both groups. Importantly, a significantly greater number of patients withdrew from the AZA group, primarily for lack of therapeutic response, which may have masked differences between the two groups.",
"   </p>",
"   <p>",
"    In nonrandomized data from the International Society for Heart and Lung Transplantation (ISHLT) registry, MMF is associated with a decreased rate of acute rejection in the first year post transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/2\">",
"     2",
"    </a>",
"    ]. Acute rejection occurred in 40 percent of those receiving the combination of",
"    <span class=\"nowrap\">",
"     MMF/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"      cyclosporine",
"     </a>",
"    </span>",
"    compared with 60 percent among those on",
"    <span class=\"nowrap\">",
"     AZA/cyclosporine.",
"    </span>",
"    The advantage of MMF over AZA may depend on the associated calcineurin inhibitor, as the difference in effect on acute rejection between MMF and AZA was less apparent when the drugs were combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . Acute rejection occurred in 30 percent of those on",
"    <span class=\"nowrap\">",
"     MMF/tacrolimus",
"    </span>",
"    compared with 35 percent among those on",
"    <span class=\"nowrap\">",
"     AZA/tacrolimus.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758321\">",
"    <span class=\"h2\">",
"     mTOR inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    are mTOR inhibitors; they have a similar structure to the calcineurin inhibitors, but exert their immunosuppressive effects through calcineurin-independent mechanisms. (See",
"    <a class=\"local\" href=\"#H32758265\">",
"     'Calcineurin inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758328\">",
"    <span class=\"h3\">",
"     Sirolimus/everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    is a macrolide antibiotic, derived from the actinomycete",
"    <em>",
"     Streptomyces hygroscopicus",
"    </em>",
"    , with potent antifungal and immunosuppressive properties;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    is a derivative of sirolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. mTOR inhibitors exert their immunosuppressive effect by binding to FKBP12, a member of the immunophilin protein family. The mTOR inhibitor-FKBP12 complex blocks the mammalian target of rapamycin (mTOR), thereby interrupting DNA and protein synthesis and proliferation of T, NK, and B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Both drugs also inhibit fibroblast proliferation resulting in poor wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mTOR inhibitors have significant adverse effects, they are typically reserved for patients who do not tolerate the nucleotide blocking agents or have allograft rejection that is refractory to nucleotide blocking agents (See",
"    <a class=\"local\" href=\"#H32758293\">",
"     'Nucleotide blocking agents'",
"    </a>",
"    above.) Thus, mTOR inhibitors are added, when needed, later in the course after transplantation. Among patients who received lung transplants between January 2002 and June 2009, 18 percent were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    at their five year follow-up, compared with 1 percent at one year post transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mTOR inhibitors are associated with substantial adverse effects, including airway anastomotic dehiscence, serious infection, hyperlipidemia, hypercholesterolemia, renal insufficiency, and cytopenias [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]. Two randomized trials of lung transplant recipients have shown a significant increase in serious adverse events and poor tolerance associated with mTOR inhibitors compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Adverse effects led to greater early discontinuation of the mTOR inhibitor (64 percent) versus azathioprine (49 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several fatal cases of anastomotic bronchial dehiscence have been reported when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    was used in the first 90 days following lung transplantation, so initiation of sirolimus and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    should be delayed at least until the bronchial anastomosis is completely healed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    is 2 mg per day orally;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    is initiated at 1.5 mg twice daily. The therapeutic ranges for sirolimus and everolimus blood levels are 5 to 15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and 3 to 12",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    respectively. Dosing information is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef60918 \" href=\"UTD.htm?19/41/20127\">",
"     table 1",
"    </a>",
"    ). Due to synergistic effects, the dose of concomitant calcineurin inhibitors should be decreased by two-thirds after starting sirolimus or everolimus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26121?source=see_link&amp;anchor=H26#H26\">",
"     \"Airway complications after lung transplantation\", section on 'Delaying use of sirolimus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    are metabolized by the cytochrome p450 enzyme system, thus dose adjustment is necessary in the presence of hepatic dysfunction and with concomitant use of other agents metabolized by the same pathway. Inhibitors and inducers of the P450 enzyme system should be added cautiously to the recipient's regimen; coadministration of imidazole anti-fungal drugs should be avoided (",
"    <a class=\"graphic graphic_table graphicRef81998 \" href=\"UTD.htm?14/44/15042\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    may be associated with an increased risk of venous thromboembolism (VTE). In a study of 181 lung transplant recipients randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , sirolimus, plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    compared with those assigned to tacrolimus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , plus prednisone, those in the sirolimus group had an increased risk of VTE (HR 5.2, 95% CI 1.4-19.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/47\">",
"     47",
"    </a>",
"    ]. Additional study is needed to determine whether this finding is replicated in other centers.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    has also been implicated in drug-induced interstitial pneumonia following renal, liver, and lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Other pulmonary complications associated with sirolimus are organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia [BOOP]), lymphocytic interstitial infiltrates, and alveolar hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Discontinuation of sirolimus resulted in clinical improvement in pneumonitis within two weeks.",
"   </p>",
"   <p>",
"    Other major side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    include dyslipidemia and myelosuppression. The combination of sirolimus and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has caused synergistic nephrotoxicity in animals, although sirolimus is minimally nephrotoxic when used alone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/53\">",
"     53",
"    </a>",
"    ]. Limited data suggest that sirolimus can be used in patients with chronic renal insufficiency due to cyclosporine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and may result in some degree of renal recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=see_link&amp;anchor=H19#H19\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    <strong>",
"     versus",
"     <span class=\"nowrap\">",
"     </span>",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    <strong>",
"     /",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    &mdash; Sirolimus and everolimus have been compared with azathioprine in two randomized trials. While reduced rates of acute rejection were seen with everolimus in one trial, this was offset by significantly higher rates of adverse events associated with these agents. Additional data are needed to clarify the appropriate role of everolimus in maintenance immunosuppression regimens following lung transplantation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 213 patients who had undergone lung transplantation were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (1 to 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and glucocorticoids as maintenance therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/45\">",
"       45",
"      </a>",
"      ]. In the first year, everolimus treatment resulted in fewer episodes of acute rejection (8 versus 32 percent) and less deterioration (9 versus 20 percent) in forced expiratory volume in one second (FEV1), a marker for chronic rejection. However, only the difference in acute rejection rates remained significant after two years. Everolimus treatment resulted in more adverse effects including serious bacterial and fungal infections, pneumonia, hyperlipidemia, hypercholesterolemia, anemia, and thrombocytopenia.",
"     </li>",
"     <li>",
"      In a multicenter trial, 181 lung transplant recipients were randomly assigned to continue",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or switch to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      at 90 days in a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      based immunosuppressive regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/46\">",
"       46",
"      </a>",
"      ]. At 1 year after transplantation, there was no significant difference in the incidence of grade A acute rejection (",
"      <a class=\"graphic graphic_table graphicRef61800 \" href=\"UTD.htm?13/10/13484\">",
"       table 5",
"      </a>",
"      ), bronchiolitis obliterans syndrome (BOS) or graft survival between the two study groups (",
"      <a class=\"graphic graphic_table graphicRef61800 \" href=\"UTD.htm?13/10/13484\">",
"       table 5",
"      </a>",
"      ). There was a higher rate of adverse events leading to early discontinuation of sirolimus (64 percent) compared with azathioprine (49 percent) during the course of this study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13143386\">",
"    <span class=\"h1\">",
"     MONITORING AND ADJUSTING MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following discharge from the hospital after lung transplantation, patients are monitored on an ongoing basis for evidence of lung transplant rejection, adverse effects of medications, adequacy of immunosuppression and immunosuppressive drug levels (when available) (",
"    <a class=\"graphic graphic_table graphicRef83298 \" href=\"UTD.htm?19/19/19773\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The exact timing of routine lab testing following lung transplantation varies among transplant programs. A typical monitoring program obtains complete blood counts, liver function tests, blood urea nitrogen, creatinine, potassium, magnesium, glucose, and cytomegalovirus viral load (eg, polymerase chain reaction) weekly for the first month, then biweekly for two months, then monthly for three months, and then every three months (",
"    <a class=\"graphic graphic_table graphicRef83298 \" href=\"UTD.htm?19/19/19773\">",
"     table 4",
"    </a>",
"    ). A lipid panel is assessed monthly for the first few months and then every three to six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link&amp;anchor=H1635497428#H1635497428\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\", section on 'Diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unfortunately, laboratory testing that would accurately and directly assess the degree of immunosuppression is not available, so monitoring depends on indirect measures, such as drug levels and cell counts, and also graft monitoring by pulmonary function tests and biopsy. Evaluation for acute and chronic lung transplant rejection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and treatment of acute lung transplant rejection\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link&amp;anchor=H13#H13\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, maintenance immunosuppression is decreased after the first year after transplantation. Tapering decisions are made on a case by case basis depending on the individual&rsquo;s history of rejection episodes and adverse effects from the medications. In lung recipients who remain stable without acute rejection or bronchiolitis obliterans syndrome (BOS), the calcineurin inhibitor and antimetabolite levels may be reduced. Additionally, in lung recipients with persistent or virulent infections, immunosuppression may be reduced more quickly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=see_link\">",
"     \"Evaluation and treatment of acute lung transplant rejection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758356\">",
"    <span class=\"h1\">",
"     TREATMENT OF REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the maintenance therapy used, the majority of lung transplant recipients experience at least one episode of acute rejection, most commonly in the first several months after transplantation. Chronic rejection (bronchiolitis obliterans) remains a major cause of morbidity and mortality in this population. The management of acute and chronic rejection is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=see_link\">",
"     \"Evaluation and treatment of acute lung transplant rejection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758363\">",
"    <span class=\"h1\">",
"     PREVENTION OF OPPORTUNISTIC INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opportunistic infection is a major side effect of immunosuppression for organ transplantation. Regimens for prophylaxis for bacterial, fungal, and viral infections post transplant are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link&amp;anchor=H1627022736#H1627022736\">",
"     \"Bacterial infections following lung transplantation\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link&amp;anchor=H1627022774#H1627022774\">",
"     \"Bacterial infections following lung transplantation\", section on 'Vaccination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H22#H22\">",
"     \"Fungal infections following lung transplantation\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32758370\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts are being made to improve the efficacy and reduce the toxicity of immunosuppression regimens. As an example, aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CsA) is being evaluated as a method to deliver high doses of CsA directly to the lung allograft while decreasing systemic exposure and toxicity. A trial randomly assigned 58 patients to use aerosolized CsA or placebo for three days a week the first two years after lung transplant; aerosol therapy was given in addition to the usual immunosuppression regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/55\">",
"     55",
"    </a>",
"    ]. Inhaled CsA did not improve the rate of acute rejection, but did improve overall survival and extend chronic rejection-free survival. Preliminary results from a larger study suggest that inhaled CsA does not improve survival or decrease chronic rejection. Aerosolized CsA is not available",
"    <sup>",
"    </sup>",
"    commercially.",
"   </p>",
"   <p>",
"    In addition to their lipid&ndash;lowering effects, statins have antiinflammatory and immunomodulatory effects that may be beneficial in solid organ transplantation. In a retrospective series, 39 lung recipients who were prescribed statin medication for lipid-lowering were compared with 161 contemporary lung recipients not on statins [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/56\">",
"     56",
"    </a>",
"    ]. Six year survival was better in the statin group compared with the control group (91 versus 54 percent, respectively). Prospective randomized trials are needed for confirmation of these findings.",
"   </p>",
"   <p>",
"    A goal for future immunosuppressive regimens is a better understanding of their effects on inhibition of activation of T cells, depletion of alloreactive T cells, and protection of T regulatory cells and their function, in order to promote tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/57\">",
"     57",
"    </a>",
"    ]. In addition, more precise monitoring of the degree of effective immunosuppression would be helpful.",
"   </p>",
"   <p>",
"    Accurate, noninvasive methods for assessment of the net effect of combination immunosuppression regimens are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/11/12474/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19603?source=see_link\">",
"       \"Patient information: Lung transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32759467\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance immunosuppressive regimens after lung transplantation vary according to transplant center experience and recipient characteristics (eg, rejection history and individual drug tolerability). To reduce toxicity and achieve adequate suppression of allograft rejection, a combination of immunosuppressive agents is used. (See",
"      <a class=\"local\" href=\"#H32760008\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all lung transplant recipients, we recommend administration of maintenance immunosuppressive therapy to reduce the risk of acute and chronic rejection (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Maintenance regimens typically consist of three drugs, including a glucocorticoid, a calcineurin inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ), and a nucleotide blocking agent (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil) (",
"      <a class=\"graphic graphic_table graphicRef60918 \" href=\"UTD.htm?19/41/20127\">",
"       table 1",
"      </a>",
"      ). However, among these choices, the optimal regimen is not known. (See",
"      <a class=\"local\" href=\"#H32760008\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical initial dose of glucocorticoid is administered perioperatively as the equivalent of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      500 to 1000 mg, intravenously. Subsequently,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is given orally at 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, or an equivalent dose intravenously; the relative potencies of the different glucocorticoid preparations are provided in the table (",
"      <a class=\"graphic graphic_table graphicRef52276 \" href=\"UTD.htm?1/32/1547\">",
"       table 3",
"      </a>",
"      ). Dosing information is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef60918 \" href=\"UTD.htm?19/41/20127\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32758258\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When selecting a calcineurin inhibitor for the initial maintenance immunosuppression regimen, we suggest choosing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This suggestion is based on the slightly better adverse effect profile of tacrolimus and limited data suggesting possible greater efficacy with tacrolimus. Dosing information is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef60918 \" href=\"UTD.htm?19/41/20127\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32758286\">",
"       'Tacrolimus versus cyclosporine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When selecting a nucleotide blocking agent for the initial maintenance immunosuppression regimen, we suggest using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      when combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This suggestion is based on limited data suggesting possible greater efficacy with mycophenolate. Dosing information is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef60918 \" href=\"UTD.htm?19/41/20127\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32758314\">",
"       'Mycophenolate mofetil versus azathioprine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      is metabolized by the enzyme thiopurine S-methyltransferase (TPMT). Approximately 10 percent of the population has a deficiency in this enzyme, which increases the risk of acute AZA-induced myelosuppression. Some transplant centers assess TPMT status (TPMT genotype",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      TPMT enzyme activity) at the time of listing for transplant, but this is not routine practice. All patients undergo monitoring of blood counts and liver function while on AZA. Dosing information is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef60918 \" href=\"UTD.htm?19/41/20127\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of pharmacogenomics\", section on 'Thiopurine methyltransferase'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=see_link&amp;anchor=H2#H2\">",
"       \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\", section on 'TPMT enzyme determination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The mTOR inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      , are antiproliferative agents that are being investigated as possible alternatives to nucleotide blocking agents. At present, sirolimus and everolimus are typically used when a patient does not tolerate the nucleotide blocking agents or has allograft rejection that is refractory to these agents. However, sirolimus and everolimus should NOT be used at least until the bronchial anastomosis has completely healed (approximately 90 days). Earlier initiation of mTOR inhibitors after lung transplantation has been associated with fatal airway dehiscence. Dosing information is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef60918 \" href=\"UTD.htm?19/41/20127\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32758321\">",
"       'mTOR inhibitors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26121?source=see_link&amp;anchor=H26#H26\">",
"       \"Airway complications after lung transplantation\", section on 'Delaying use of sirolimus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Doses and levels of immunosuppression are often reduced after the first year following transplantation if a patient remains stable without evidence of rejection. (See",
"      <a class=\"local\" href=\"#H13143386\">",
"       'Monitoring and adjusting maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ongoing monitoring of blood counts, glucose and lipid levels, potassium, magnesium, kidney and liver function, and drug levels is essential. The specific frequency of testing varies among centers. The table shows our typical testing protocol (",
"      <a class=\"graphic graphic_table graphicRef83298 \" href=\"UTD.htm?19/19/19773\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13143386\">",
"       'Monitoring and adjusting maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many of the drugs used for maintenance immunosuppression, particularly the calcineurin and mTOR inhibitors, are metabolized by the cytochrome P450 (CYP450) enzyme system. Potential drug interactions affecting these agents, along with recommendations for alternatives, additional monitoring",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dose adjustments are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef81998 \" href=\"UTD.htm?14/44/15042\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32760008\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32758321\">",
"       'mTOR inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Opportunistic infection is a major side effect of immunosuppression for organ transplantation. Regimens for prophylaxis against bacterial, fungal and viral infections post transplant are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link&amp;anchor=H1627022736#H1627022736\">",
"       \"Bacterial infections following lung transplantation\", section on 'Prophylaxis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link&amp;anchor=H1627022774#H1627022774\">",
"       \"Bacterial infections following lung transplantation\", section on 'Vaccination'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H22#H22\">",
"       \"Fungal infections following lung transplantation\", section on 'Prophylaxis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis and treatment of acute and chronic lung transplant rejection are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=see_link\">",
"       \"Evaluation and treatment of acute lung transplant rejection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"       \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/1\">",
"      Blumenstock DA, Lewis C. The first transplantation of the lung in a human revisited. Ann Thorac Surg 1993; 56:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/2\">",
"      Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report--2010. J Heart Lung Transplant 2010; 29:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/3\">",
"      Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med 2005; 353:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/4\">",
"      Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006; 148:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/5\">",
"      Bhorade SM, Stern E. Immunosuppression for lung transplantation. Proc Am Thorac Soc 2009; 6:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/6\">",
"      Shitrit D, Bendayan D, Sulkes J, et al. Successful steroid withdrawal in lung transplant recipients: result of a pilot study. Respir Med 2005; 99:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/7\">",
"      Borro JM, Sol&eacute; A, De la Torre M, et al. Steroid withdrawal in lung transplant recipients. Transplant Proc 2005; 37:3991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/8\">",
"      Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995; 60:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/9\">",
"      Treede H, Klepetko W, Reichenspurner H, et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 2001; 20:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/10\">",
"      Zuckermann A, Reichenspurner H, Birsan T, et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg 2003; 125:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/11\">",
"      Hachem RR, Yusen RD, Chakinala MM, et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant 2007; 26:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/12\">",
"      Sarahrudi K, Carretta A, Wisser W, et al. The value of switching from cyclosporine to tacrolimus in the treatment of refractory acute rejection and obliterative bronchiolitis after lung transplantation. Transpl Int 2002; 15:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/13\">",
"      Bhorade SM, Jordan A, Villanueva J, et al. Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. Am J Transplant 2003; 3:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/14\">",
"      Unilateral lung transplantation for pulmonary fibrosis. Toronto Lung Transplant Group. N Engl J Med 1986; 314:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/15\">",
"      Kahan BD. Cyclosporine: a revolution in transplantation. Transplant Proc 1999; 31:14S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/16\">",
"      Parekh K, Trulock E, Patterson GA. Use of cyclosporine in lung transplantation. Transplant Proc 2004; 36:318S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/17\">",
"      Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J 2004; 23:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/18\">",
"      Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. Clin Pharmacokinet 2009; 48:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/19\">",
"      Briffa N, Morris RE. New immunosuppressive regimens in lung transplantation. Eur Respir J 1997; 10:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/20\">",
"      Kahan BD. Cyclosporine. N Engl J Med 1989; 321:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/21\">",
"      Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/22\">",
"      Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/23\">",
"      Watkins KD, Boettger RF, Hanger KM, et al. Use of sublingual tacrolimus in lung transplant recipients. J Heart Lung Transplant 2012; 31:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/24\">",
"      Christie JD, Edwards LB, Aurora P, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009. J Heart Lung Transplant 2009; 28:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/25\">",
"      Palmer SM, Baz MA, Sanders L, et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 2001; 71:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/26\">",
"      McNeil K, Glanville AR, Wahlers T, et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 2006; 81:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/27\">",
"      Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005; 14 Suppl 1:s2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/28\">",
"      Morris RE, Hoyt EG, Murphy MP, et al. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/29\">",
"      Kobashigawa JA, Renlund DG, Gerosa G, et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 2006; 25:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/30\">",
"      Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005; 56:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/31\">",
"      Poppe D, Tiede I, Fritz G, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006; 176:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/32\">",
"      Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/33\">",
"      Zuckermann A, Klepetko W, Birsan T, et al. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. J Heart Lung Transplant 1999; 18:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/34\">",
"      Ross DJ, Waters PF, Levine M, et al. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant 1998; 17:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/35\">",
"      Speich R, Schneider S, Hofer M, et al. Mycophenolate mofetil reduces alveolar inflammation, acute rejection and graft loss due to bronchiolitis obliterans syndrome after lung transplantation. Pulm Pharmacol Ther 2010; 23:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/36\">",
"      Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/37\">",
"      Kelly PA, Gruber SA, Behbod F, Kahan BD. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 1997; 17:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/38\">",
"      Formica RN Jr, Lorber KM, Friedman AL, et al. The evolving experience using everolimus in clinical transplantation. Transplant Proc 2004; 36:495S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/39\">",
"      Neumayer HH. Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments. Transplantation 2005; 79:S72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/40\">",
"      Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35:7S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/41\">",
"      Iverson M, Corris PA. Immunosuppression. Eur Respir Mon 2009; 45:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/42\">",
"      King-Biggs MB, Dunitz JM, Park SJ, et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003; 75:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/43\">",
"      Groetzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004; 23:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/44\">",
"      Santacruz JF, Mehta AC. Airway complications and management after lung transplantation: ischemia, dehiscence, and stenosis. Proc Am Thorac Soc 2009; 6:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/45\">",
"      Snell GI, Valentine VG, Vitulo P, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006; 6:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/46\">",
"      Bhorade S, Ahya VN, Baz MA, et al. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. Am J Respir Crit Care Med 2011; 183:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/47\">",
"      Ahya VN, McShane PJ, Baz MA, et al. Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation. J Heart Lung Transplant 2011; 30:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/48\">",
"      Morelon E, Stern M, Isra&euml;l-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/49\">",
"      Lennon A, Finan K, FitzGerald MX, McCormick PA. Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation. Transplantation 2001; 72:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/50\">",
"      McWilliams TJ, Levvey BJ, Russell PA, et al. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant 2003; 22:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/51\">",
"      Lindenfeld JA, Simon SF, Zamora MR, et al. BOOP is common in cardiac transplant recipients switched from a calcineurin inhibitor to sirolimus. Am J Transplant 2005; 5:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/52\">",
"      Vlahakis NE, Rickman OB, Morgenthaler T. Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 2004; 79:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/53\">",
"      Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/54\">",
"      Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/55\">",
"      Iacono AT, Johnson BA, Grgurich WF, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 2006; 354:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/56\">",
"      Johnson BA, Iacono AT, Zeevi A, et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003; 167:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/57\">",
"      Floreth T, Bhorade SM, Ahya VN. Conventional and novel approaches to immunosuppression. Clin Chest Med 2011; 32:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/11/12474/abstract/58\">",
"      Wieland E, Olbricht CJ, S&uuml;sal C, et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit 2010; 32:560.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16734 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12474=[""].join("\n");
var outline_f12_11_12474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32759467\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32759821\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32760008\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32760049\">",
"      AGENTS FOR MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32758258\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32758265\">",
"      Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32758272\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32758279\">",
"      - Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32758286\">",
"      - Tacrolimus versus cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32758293\">",
"      Nucleotide blocking agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32758300\">",
"      - Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32758307\">",
"      - Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32758314\">",
"      - Mycophenolate mofetil versus azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32758321\">",
"      mTOR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32758328\">",
"      - Sirolimus/everolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13143386\">",
"      MONITORING AND ADJUSTING MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32758356\">",
"      TREATMENT OF REJECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32758363\">",
"      PREVENTION OF OPPORTUNISTIC INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32758370\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32759467\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/16734\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/16734|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/41/20127\" title=\"table 1\">",
"      Maintenance agents for lung transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/44/15042\" title=\"table 2\">",
"      Drug interactions with immunosuppressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/32/1547\" title=\"table 3\">",
"      Steroid compound dose equiv",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/19/19773\" title=\"table 4\">",
"      Sample schedule for laboratory tests after lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/10/13484\" title=\"table 5\">",
"      Pulmonary allograft rejection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=related_link\">",
"      6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26121?source=related_link\">",
"      Airway complications after lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=related_link\">",
"      Evaluation and treatment of acute lung transplant rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3688?source=related_link\">",
"      Induction immunosuppression following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3480?source=related_link\">",
"      Lung transplantation: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19603?source=related_link\">",
"      Patient information: Lung transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_11_12475="Rapid sequence intubation seven Ps timing";
var content_f12_11_12475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary: The Seven Ps of rapid sequence intubation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preparation",
"       </td>",
"       <td>",
"        10 minutes before intubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preoxygenation",
"       </td>",
"       <td>",
"        5 minutes before intubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pretreatment",
"       </td>",
"       <td>",
"        3 minutes before intubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paralysis with induction",
"       </td>",
"       <td>",
"        Induction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protection",
"       </td>",
"       <td>",
"        30 seconds after induction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placement (Intubation)",
"       </td>",
"       <td>",
"        45 seconds after induction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-intubation management",
"       </td>",
"       <td>",
"        60 seconds after induction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12475=[""].join("\n");
var outline_f12_11_12475=null;
var title_f12_11_12476="MMR in adults";
var content_f12_11_12476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    MMR vaccine in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antibody response",
"       </td>",
"       <td class=\"subtitle1\">",
"        Protection against disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Most common side effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        MMR",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Single dose: 0.5 mL SC",
"        </p>",
"        <p>",
"         Second dose if required: 0.5 mL SC at least 28 days later",
"        </p>",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Most rare after revaccination",
"        </p>",
"        <p>",
"         Fever, rash",
"        </p>",
"        <p>",
"         Lymphadenopathy",
"        </p>",
"        <p>",
"         Febrile seizures",
"        </p>",
"        <p>",
"         Allergic reactions",
"        </p>",
"        <p>",
"         Thrombocytopenia",
"        </p>",
"        <p>",
"         Arthritis, arthralgias",
"        </p>",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Pregnancy current or planned within 28 days",
"        </p>",
"        <p>",
"         Immunocompromised (see related topics)",
"        </p>",
"        <p>",
"         Anaphylaxis after eating eggs or receiving neomycin",
"        </p>",
"        <p>",
"         Recent administration of immune globulin (delay vaccine administration for at least five months in immunocompetent hosts and for at least six months in immunocompromised hosts)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Measles",
"       </td>",
"       <td>",
"        99% (after 2 doses)",
"       </td>",
"       <td>",
"        99% - Lifelong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mumps",
"       </td>",
"       <td>",
"        97% (after 1 dose)",
"       </td>",
"       <td>",
"        75-95% &gt;30 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rubella",
"       </td>",
"       <td>",
"        95% (after 1 dose)",
"       </td>",
"       <td>",
"        90% &gt;15 years ? lifelong",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MMR: Measles-Mumps-Rubella; SC: subcutaneously; %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Watson JC, Pearson JA, Markowitz LE, et al. Pediatrics 1996; 97:613; Weibel RE, Sokes J Jr, Buynak EB, et al. N Engl J Med 1967; 276:245; Balfour HH, Groth KE, Edelman CK. Am J Dis Child 1990; 134:350; O'Shea S, Best JM, Banatvala JE. J Infect Dis 1983; 148:639; Watson JC, Hadler SC, Dykewicz CA, et al. MMWR Recomm Rep 1998; 47:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12476=[""].join("\n");
var outline_f12_11_12476=null;
var title_f12_11_12477="Common vulvar lesions 1";
var content_f12_11_12477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Most vulvar lesions based on morphology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Morphology",
"      </td>",
"      <td class=\"subtitle1\">",
"       Color",
"      </td>",
"      <td class=\"subtitle1\">",
"       Common diseases",
"      </td>",
"      <td class=\"subtitle1\">",
"       Infection",
"      </td>",
"      <td class=\"subtitle1\">",
"       Malignancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"8\">",
"       Papules, nodules",
"      </td>",
"      <td colspan=\"1\" rowspan=\"8\">",
"       Flesh- colored",
"      </td>",
"      <td>",
"       Vestibular papillae",
"      </td>",
"      <td>",
"       Genital warts",
"      </td>",
"      <td>",
"       Soft tissue malignancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cyst",
"      </td>",
"      <td>",
"       Molluscum contagiosum",
"      </td>",
"      <td colspan=\"1\" rowspan=\"7\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Syringoma",
"      </td>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hidradenoma papilliferum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Skin tag",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neurofibroma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lipoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fibroma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Patch, plaque",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       White",
"      </td>",
"      <td>",
"       Post-inflammatory hypopigmentation",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       &nbsp;",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyperkeratosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vitiligo",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lichen sclerosis et atrophicus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"5\">",
"       Macule, patch",
"      </td>",
"      <td colspan=\"1\" rowspan=\"5\">",
"       Dark",
"      </td>",
"      <td>",
"       Physiologic",
"      </td>",
"      <td colspan=\"1\" rowspan=\"5\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       Melanoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Post-inflammatory hyperpigmentation",
"      </td>",
"      <td>",
"       Vulvar intraepithelial neoplasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Genital lentigenes",
"      </td>",
"      <td>",
"       Carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Junctional nevi",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acanthosis nigricans",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       Papule, nodule",
"      </td>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       Dark",
"      </td>",
"      <td>",
"       Seborrheic keratosis",
"      </td>",
"      <td>",
"       Genital warts",
"      </td>",
"      <td>",
"       Dysplastic nevi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dermatofibroma",
"      </td>",
"      <td>",
"       Bowenoid papulosis",
"      </td>",
"      <td>",
"       Melanoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ectopic breast tissue",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       Kaposi's sarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fox-Fordyce",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Compound melanocytic nevi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intradermal nevi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"8\">",
"       Macule, patch, plaque",
"      </td>",
"      <td colspan=\"1\" rowspan=\"8\">",
"       Red",
"      </td>",
"      <td>",
"       Atopic dermatitis",
"      </td>",
"      <td>",
"       Candida",
"      </td>",
"      <td>",
"       Bowen's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neurodermatitis",
"      </td>",
"      <td>",
"       Dermatophyte",
"      </td>",
"      <td>",
"       Carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Contact dermatitis",
"      </td>",
"      <td>",
"       Erythrasma",
"      </td>",
"      <td>",
"       Carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Psoriasis",
"      </td>",
"      <td>",
"       Bacterial vaginosis",
"      </td>",
"      <td>",
"       Extramammary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reiter's disease",
"      </td>",
"      <td>",
"       Trichomoniasis",
"      </td>",
"      <td>",
"       Paget's",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lichen planus",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       &nbsp;",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Zoon's plasma cell vulvitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12477=[""].join("\n");
var outline_f12_11_12477=null;
var title_f12_11_12478="MIP and lung hyperinflation";
var content_f12_11_12478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperinflation (increased RV/TLC) causes a reduced maximal inspiratory (MIP) in many patients with COPD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 412px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The MIP is 100 percent of its predicted value when the RV/TLC is in its normal range (20 to 35 percent depending on age). MIP decreases as RV/TLC increases because diaphragm muscles begin to operate at a mechanical disadvantage. As an example (dashed lines), a 55-year-old man with severe COPD and severe hyperinflation (RV/TLC of 85 percent) has a MIP that is only 50 percent of its predicted value (50 cmH",
"    <sub>",
"     2",
"    </sub>",
"    O instead of 100 cmH",
"    <sub>",
"     2",
"    </sub>",
"    O), despite having good nutrition and normal inspiratory muscle strength.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Rochester DF. Tests of respiratory muscle function. Clinics Chest Med 1988; 9:249-261.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12478=[""].join("\n");
var outline_f12_11_12478=null;
var title_f12_11_12479="Potential source GH excess";
var content_f12_11_12479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Potential sources of growth hormone excess within the GH axis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 556px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) normal axis; (B) increased hypothalmic GHRH secretion; (C) increased pituitary GH secretion; (D) decreased somatostatin tone.",
"    <div class=\"footnotes\">",
"     GHRH: growth-hormone releasing hormone; SS: somatostatin; GH: growth hormone; IGF-1: insulin-like growth factor-1.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Erica A Eugster, MD and Ora H Pescovitz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_11_12479=[""].join("\n");
var outline_f12_11_12479=null;
